Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 764 articles:
HTML format



Single Articles


    February 2024
  1. KRUSE C, Lipinski A, Verheyen M, Balzer-Geldsetzer M, et al
    Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries.
    Mov Disord. 2024 Feb 29. doi: 10.1002/mds.29718.
    PubMed     Abstract available


  2. WILKEN M, Andres DS, Bianchi G, Hallett M, et al
    Persistence of Basal Ganglia Oscillatory Activity During Tremor Attenuation by Movement in Parkinson's Disease Patients.
    Mov Disord. 2024 Feb 28. doi: 10.1002/mds.29679.
    PubMed     Abstract available


  3. OJO OO, Bandres-Ciga S, Makarious MB, Crea PW, et al
    GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29753.
    PubMed     Abstract available


  4. DORSEY ER, Kinel D, Pawlik ME, Zafar M, et al
    Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29723.
    PubMed     Abstract available


  5. AMBROSINI E, Cancilla R, Paul JJ, Bauer P, et al
    Pure Parkinsonism as Possible Phenotype Expansion of THAP1-Related Disorders.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29745.
    PubMed    


  6. SOLIS GP, Larasati YA, Thiel M, Koval A, et al
    GNAO1 Mutations Affecting the N-Terminal alpha-Helix of Galphao Lead to Parkinsonism.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29720.
    PubMed     Abstract available


  7. PAPAGIANNAKIS N, Liu H, Koros C, Simitsi AM, et al
    Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin-Related Parkinson's Disease.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29739.
    PubMed     Abstract available


  8. WEINTRAUB D, Marras C, Amara A, Anderson KE, et al
    Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease.
    Mov Disord. 2024 Feb 6. doi: 10.1002/mds.29725.
    PubMed     Abstract available


  9. KULCSAROVA K, Skorvanek M
    Challenges and Future of the International Parkinson and Movement Disorder Society Prodromal Parkinson's Disease Criteria: Are We On the Right Track?
    Mov Disord. 2024 Feb 4. doi: 10.1002/mds.29724.
    PubMed    


  10. YUAN X, Wan L, Chen Z, Long Z, et al
    Peripheral Inflammatory and Immune Landscape in Multiple System Atrophy: A Cross-Sectional Study.
    Mov Disord. 2024;39:391-399.
    PubMed     Abstract available


    January 2024
  11. FOLLETT J, Guenther D, Xoi L, Amouri R, et al
    Genetic Modifiers of LRRK2 Parkinson's Disease: A Replication Study in Arab-Berbers.
    Mov Disord. 2024 Jan 31. doi: 10.1002/mds.29735.
    PubMed    


  12. MANGONE G, Tosin MHS, Goetz CG, Stebbins GT, et al
    Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29710.
    PubMed     Abstract available


  13. DAMIER P, Degos B, Castelonovo G, Anheim M, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29726.
    PubMed     Abstract available


  14. MARRAS C, Fereshtehnejad SM, Berg D, Bohnen NI, et al
    Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29708.
    PubMed     Abstract available


  15. EIDEM LE, Birkeland E, Austdal M, Bardsen K, et al
    Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29715.
    PubMed    


  16. DEBOVE I, Paschen S, Amstutz D, Cardoso F, et al
    Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus.
    Mov Disord. 2024 Jan 17. doi: 10.1002/mds.29700.
    PubMed     Abstract available


  17. ROSE KN, Schwarzschild MA, Gomperts SN
    Clearing the Smoke: What Protects Smokers from Parkinson's Disease?
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29707.
    PubMed     Abstract available


  18. MULLER S, Kassubek J, Hold ST, Kasper DC, et al
    Morbus Fabry and Parkinson's Disease-More Evidence for a Possible Genetic Link.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29686.
    PubMed    


  19. TUNNICLIFFE L, Weil RS, Breuer J, Rodriguez-Barradas MC, et al
    Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29701.
    PubMed     Abstract available


  20. AMMANN C, Oliviero A, Obeso JA, Foffani G, et al
    Motor Cortex Disinhibition Is Not Associated with Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2024 Jan 5. doi: 10.1002/mds.29709.
    PubMed    


  21. THOMAS GEC, Hannaway N, Zarkali A, Shmueli K, et al
    Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29702.
    PubMed     Abstract available


  22. SICILIANO M, Tessitore A, Morgante F, Goldman JG, et al
    Subjective Cognitive Complaints in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29649.
    PubMed     Abstract available


  23. DOMEN CH, Sillau S, Liu Y, Leehey MA, et al
    Reply to: Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2024;39:222-223.
    PubMed    


  24. GAN-OR Z, Alcalay RN
    Genetics of Parkinson's Disease in Underrepresented Populations: New Studies Pave the Way.
    Mov Disord. 2024;39:1-2.
    PubMed    


  25. BEUDEL M
    Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
    Mov Disord. 2024;39:223-224.
    PubMed    


  26. SAMPSON TR
    Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut.
    Mov Disord. 2024;39:3-5.
    PubMed    


  27. RAU A, Hosp JA, Rijntjes M, Weiller C, et al
    Cerebellar, Not Nigrostriatal Degeneration Impairs Dexterity in Multiple System Atrophy.
    Mov Disord. 2024;39:130-140.
    PubMed     Abstract available


  28. KRISMER F, Peran P, Beliveau V, Seppi K, et al
    Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study.
    Mov Disord. 2024;39:119-129.
    PubMed     Abstract available


  29. HILL ME, Johnson LA, Wang J, Escobar Sanabria D, et al
    Paradoxical Modulation of STN beta-Band Activity with Medication Compared to Deep Brain Stimulation.
    Mov Disord. 2024;39:192-197.
    PubMed     Abstract available


    December 2023
  30. MIRELMAN A, Volkov J, Salomon A, Gazit E, et al
    Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease.
    Mov Disord. 2023 Dec 27. doi: 10.1002/mds.29689.
    PubMed     Abstract available


  31. ONG S, Funayama M, Mangyoku Y, Kawai H, et al
    Investigation of 22q11.2 Deletion in Japanese Early-Onset Parkinsonism.
    Mov Disord. 2023 Dec 25. doi: 10.1002/mds.29692.
    PubMed    


  32. JANSSEN DAALEN JM, Koopman WJH, Saris CGJ, Meinders MJ, et al
    The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?
    Mov Disord. 2023 Dec 23. doi: 10.1002/mds.29688.
    PubMed     Abstract available


  33. BAIK K, Kim YJ, Park M, Chung SJ, et al
    Functional Brain Networks of Minor and Well-Structured Major Hallucinations in Parkinson's Disease.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29681.
    PubMed     Abstract available


  34. GONZALEZ-ROBLES C, Bartlett M, Burnell M, Clarke CS, et al
    Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29691.
    PubMed     Abstract available


  35. TUNOLD JA, Tan MMX, Toft M, Ross O, et al
    Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk.
    Mov Disord. 2023 Dec 20. doi: 10.1002/mds.29698.
    PubMed     Abstract available


  36. ESPAY AJ, Hauser RA, Dhall R, Thakkar S, et al
    Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29685.
    PubMed     Abstract available


  37. MARANO M, Anzini G, Saltarocchi L, Ricciuti R, et al
    Left Vagus Stimulation Modulates Contralateral Subthalamic beta Power Improving the Gait in Parkinson's Disease.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29690.
    PubMed     Abstract available


  38. CARDOSO F, Goetz CG, Mestre TA, Sampaio C, et al
    A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease.
    Mov Disord. 2023 Dec 13. doi: 10.1002/mds.29683.
    PubMed    


  39. MYLIUS V, Baars JH, Witt K, Benninger D, et al
    Deep Brain Stimulation Improves Parkinson's Disease-Associated Pain by Decreasing Spinal Nociception.
    Mov Disord. 2023 Dec 9. doi: 10.1002/mds.29666.
    PubMed     Abstract available


  40. KIM DJ, Isidro-Perez AL, Doering M, Llibre-Rodriguez JJ, et al
    Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta-Analysis.
    Mov Disord. 2023 Dec 8. doi: 10.1002/mds.29682.
    PubMed     Abstract available


  41. BRISSENDEN JA, Scerbak T, Albin RL, Lee TG, et al
    Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
    Mov Disord. 2023 Dec 7. doi: 10.1002/mds.29659.
    PubMed     Abstract available


  42. FIORENZATO E, Moaveninejad S, Weis L, Biundo R, et al
    Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2023 Dec 6. doi: 10.1002/mds.29678.
    PubMed     Abstract available


  43. MULLER T, Kuhn W
    An Indirect Proof for Levodopa-Induced Vitamin Deficiency in Parkinson's Disease.
    Mov Disord. 2023;38:2319-2320.
    PubMed    


  44. NAMBU A, Chiken S, Sano H, Hatanaka N, et al
    Dynamic Activity Model of Movement Disorders: The Fundamental Role of the Hyperdirect Pathway.
    Mov Disord. 2023;38:2145-2150.
    PubMed     Abstract available


  45. ZHENG Y, Cai H, Wang X, Zhang N, et al
    Erythrocytic alpha-Synuclein Species as Biomarkers for Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:2315-2317.
    PubMed    


    November 2023
  46. ANDREWS SV, Kukkle PL, Menon R, Geetha TS, et al
    The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in India.
    Mov Disord. 2023 Nov 28. doi: 10.1002/mds.29676.
    PubMed     Abstract available


  47. WANG J, Li H, Jia J, Shao X, et al
    Progressive Cerebrovascular Reactivity Reduction Occurs in Parkinson's Disease: A Longitudinal Study.
    Mov Disord. 2023 Nov 27. doi: 10.1002/mds.29671.
    PubMed     Abstract available


  48. ONGARI G, Ghezzi C, Di Martino D, Pisani A, et al
    Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease?
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29643.
    PubMed     Abstract available


  49. DI FOLCO C, Couronne R, Arnulf I, Mangone G, et al
    Charting Disease Trajectories from Isolated REM Sleep Behavior Disorder to Parkinson's Disease.
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29662.
    PubMed     Abstract available



  50. Correction to Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Nov 22. doi: 10.1002/mds.29660.
    PubMed    


  51. MA DR, Li SJ, Shi JJ, Liang YY, et al
    Shared Genetic Architecture between Parkinson's Disease and Brain Structural Phenotypes.
    Mov Disord. 2023 Nov 21. doi: 10.1002/mds.29598.
    PubMed     Abstract available


  52. KIM A, Martinez-Valbuena I, Keith JL, Kovacs GG, et al
    Misfolded alpha-Synuclein Seeding Is Detected in Suspected LRRK2-Parkinson's Disease without Immunohistochemically Detectable alpha-Synuclein Pathology.
    Mov Disord. 2023 Nov 20. doi: 10.1002/mds.29665.
    PubMed    


  53. BOOGERS A, Fasano A
    A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Nov 15. doi: 10.1002/mds.29656.
    PubMed    


  54. KERESTES R, Laansma MA, Owens-Walton C, Perry A, et al
    Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study.
    Mov Disord. 2023 Nov 14. doi: 10.1002/mds.29611.
    PubMed     Abstract available


  55. OERTEL WH, Paule E, Hasemann T, Sittig E, et al
    Reduced Gastric Contraction in Rapid-Eye-Movement Sleep Behavior Disorder and De Novo Parkinson's Disease.
    Mov Disord. 2023 Nov 13. doi: 10.1002/mds.29652.
    PubMed     Abstract available


  56. KONERU V, Espay AJ, Cole AJ, Weintraub D, et al
    The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP).
    Mov Disord. 2023 Nov 8. doi: 10.1002/mds.29627.
    PubMed     Abstract available


  57. DAIDA K, Funayama M, Billingsley KJ, Malik L, et al
    Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
    Mov Disord. 2023 Nov 5. doi: 10.1002/mds.29610.
    PubMed     Abstract available


  58. SAFFIE AWAD P, Teixeira-Dos-Santos D, Santos-Lobato BL, Camargos S, et al
    Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Nov 3. doi: 10.1002/mds.29614.
    PubMed     Abstract available


  59. PAL GD, Corcos DM, Metman LV, Israel Z, et al
    Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants.
    Mov Disord. 2023 Nov 2. doi: 10.1002/mds.29647.
    PubMed     Abstract available



  60. The Future of Parkinson's Disease: Improving Care & Driving Research.
    Mov Disord. 2023;38 Suppl 2:S1-S21.
    PubMed    


  61. BERGER SL, Seemiller J, Rosenthal LS
    Synuclein Seed Amplification in the Cerebrospinal Fluid: Research and Clinical Implications.
    Mov Disord. 2023;38:1990-1991.
    PubMed    


  62. VASILEVSKAYA A, Martinez-Valbuena I, Anastassiadis C, Taghdiri F, et al
    Misfolded alpha-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes.
    Mov Disord. 2023;38:2125-2131.
    PubMed     Abstract available


  63. DI LUCA DG, Ramirez-Gomez C, Germann J, Santyr B, et al
    Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy.
    Mov Disord. 2023;38:2121-2125.
    PubMed     Abstract available


    October 2023
  64. OLANOW CW, Hauser RA, Burdick DJ, Dhall R, et al
    A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
    Mov Disord. 2023 Oct 27. doi: 10.1002/mds.29642.
    PubMed     Abstract available


  65. PAHWA R, Merola A, Soileau M, Alobaidi A, et al
    Cost-Effectiveness of Carbidopa-Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States.
    Mov Disord. 2023 Oct 25. doi: 10.1002/mds.29624.
    PubMed     Abstract available


  66. BOUGOU V, Vanhoyland M, Decramer T, Van Hoylandt A, et al
    Active and Passive Cycling Decrease Subthalamic beta Oscillations in Parkinson's Disease.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29632.
    PubMed     Abstract available


  67. CONTI M, Guerra A, Pierantozzi M, Bovenzi R, et al
    Band-Specific Altered Cortical Connectivity in Early Parkinson's Disease and its Clinical Correlates.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29615.
    PubMed     Abstract available


  68. ALBIN R, Grotewold N
    What is the Parkinson Pandemic?
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29637.
    PubMed    


  69. WOO KA, Joun JH, Yoon EJ, Lee CY, et al
    Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease.
    Mov Disord. 2023 Oct 17. doi: 10.1002/mds.29623.
    PubMed     Abstract available


  70. BUSCH JL, Kaplan J, Bahners BH, Roediger J, et al
    Local Field Potentials Predict Motor Performance in Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Oct 12. doi: 10.1002/mds.29626.
    PubMed     Abstract available


  71. SAMUEL N, Ding MYR, Sarica C, Darmani G, et al
    Accelerated Transcranial Ultrasound Neuromodulation in Parkinson's Disease: A Pilot Study.
    Mov Disord. 2023 Oct 9. doi: 10.1002/mds.29622.
    PubMed     Abstract available


  72. YANG Y, Stewart T, Zhang C, Wang P, et al
    Erythrocytic alpha-Synuclein and the Gut Microbiome: Kindling of the Gut-Brain Axis in Parkinson's Disease.
    Mov Disord. 2023 Oct 5. doi: 10.1002/mds.29620.
    PubMed     Abstract available


  73. WAN L, Fu Y, Chen Z, Long Z, et al
    No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts.
    Mov Disord. 2023;38:1956-1961.
    PubMed     Abstract available


  74. HU Y, Ma TC, Alberico SL, Ding Y, et al
    Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
    Mov Disord. 2023;38:1850-1860.
    PubMed     Abstract available


  75. GROSSMANN D, Malburg N, Glass H, Weeren V, et al
    Mitochondria-Endoplasmic Reticulum Contact Sites Dynamics and Calcium Homeostasis Are Differentially Disrupted in PINK1-PD or PRKN-PD Neurons.
    Mov Disord. 2023;38:1822-1836.
    PubMed     Abstract available


    September 2023
  76. JANSSEN DAALEN JM, Oosterhof TH, Bloem BR, Darweesh SKL, et al
    Wearables for Parkinson's: Fast-Paced toward Novel Outcome Measures.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29608.
    PubMed    


  77. SATOH R, Weigand SD, Pham NTT, Ali F, et al
    Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29613.
    PubMed     Abstract available


  78. DI FONZO A, Percetti M, Monfrini E, Palmieri I, et al
    Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study.
    Mov Disord. 2023 Sep 26. doi: 10.1002/mds.29617.
    PubMed     Abstract available


  79. TOFFOLI M, Schapira AHV, Proukakis C
    Sex Distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson's Disease.
    Mov Disord. 2023 Sep 22. doi: 10.1002/mds.29609.
    PubMed    


  80. NATALE G, Colella M, De Carluccio M, Lelli D, et al
    Astrocyte Responses Influence Local Effects of Whole-Brain Magnetic Stimulation in Parkinsonian Rats.
    Mov Disord. 2023 Sep 12. doi: 10.1002/mds.29599.
    PubMed     Abstract available


  81. ZHAO Y, Ray A, Broberg K, Kippler M, et al
    Prediagnostic Blood Metal Levels and the Risk of Parkinson's Disease: A Large European Prospective Cohort.
    Mov Disord. 2023 Sep 7. doi: 10.1002/mds.29602.
    PubMed     Abstract available


  82. BOOIJ J, Tellier SP, Seibyl J, Vriend C, et al
    Dopamine Transporter Availability in Early Parkinson's Disease is Dependent on Sunlight Exposure.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29597.
    PubMed     Abstract available


  83. MARKAKI I, Paslawski W, Ntetsika T, Engesvik L, et al
    Isolation of L1CAM-Extracellular Vesicles Reveals Signs of Insulin Resistance in Parkinson's Disease.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29601.
    PubMed    



  84. Correction to "Olfactory Neuron Substance P Is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction".
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29600.
    PubMed    


  85. FINK A, Dodel R, Georges D, Doblhammer G, et al
    The Impact of Sex-Specific Survival on the Incidence of Dementia in Parkinson's Disease.
    Mov Disord. 2023 Sep 1. doi: 10.1002/mds.29596.
    PubMed     Abstract available


  86. BOON LI, Buijink AWG
    Parkinsonian Tremor: Shaking in Synchrony.
    Mov Disord. 2023;38:1582-1584.
    PubMed    


  87. GONZALEZ-LATAPI P, Lo RY
    Bone First or Brain First: "Picking at the Bones" of Parkinson's Disease.
    Mov Disord. 2023;38:1579-1581.
    PubMed    


  88. ZHANG D, Zhou L, Yao J, Shi Y, et al
    Increased Free Water in the Putamen in Idiopathic REM Sleep Behavior Disorder.
    Mov Disord. 2023;38:1645-1654.
    PubMed     Abstract available


    August 2023
  89. SUN H, Gan C, Wang L, Ji M, et al
    Cortical Disinhibition Drives Freezing of Gait in Parkinson's Disease and an Exploratory Repetitive Transcranial Magnetic Stimulation Study.
    Mov Disord. 2023 Aug 30. doi: 10.1002/mds.29595.
    PubMed     Abstract available


  90. TOTSUNE T, Baba T, Sugimura Y, Oizumi H, et al
    Nuclear Imaging Data-Driven Classification of Parkinson's Disease.
    Mov Disord. 2023 Aug 28. doi: 10.1002/mds.29582.
    PubMed     Abstract available


  91. WEINTRAUB D
    What's in a Name? The Time Has Come to Unify Parkinson's Disease and Dementia with Lewy Bodies.
    Mov Disord. 2023 Aug 23. doi: 10.1002/mds.29590.
    PubMed    


  92. ANDICA C, Kamagata K, Uchida W, Saito Y, et al
    Fiber-Specific White Matter Alterations in Parkinson's Disease Patients with GBA Gene Mutations.
    Mov Disord. 2023 Aug 22. doi: 10.1002/mds.29578.
    PubMed     Abstract available


  93. PARK KY, Jung JH, Hwang HS, Park HK, et al
    Bone Mineral Density and the Risk of Parkinson's Disease in Postmenopausal Women.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29579.
    PubMed     Abstract available


  94. TRESSERRA-RIMBAU A, Thompson AS, Bondonno N, Jennings A, et al
    Plant-Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29580.
    PubMed     Abstract available


  95. DAI L, Wang J, Zhang X, Yan M, et al
    27-Hydroxycholesterol Drives the Spread of alpha-Synuclein Pathology in Parkinson's Disease.
    Mov Disord. 2023 Aug 18. doi: 10.1002/mds.29577.
    PubMed     Abstract available


  96. BAR-ON M, Baharav S, Katzir Z, Mirelman A, et al
    Task-Related Reorganization of Cognitive Network in Parkinson's Disease Using Electrophysiology.
    Mov Disord. 2023 Aug 8. doi: 10.1002/mds.29571.
    PubMed     Abstract available


  97. GAARE JJ, Brugger K, Nido GS, Tzoulis C, et al
    DNA Methylation Age Acceleration Is Not Associated with Age of Onset in Parkinson's Disease.
    Mov Disord. 2023 Aug 7. doi: 10.1002/mds.29574.
    PubMed     Abstract available


  98. CHU Y, Kordower JH
    Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery.
    Mov Disord. 2023 Aug 6. doi: 10.1002/mds.29518.
    PubMed     Abstract available


  99. TA M, Blauwendraat C, Antar T, Leonard HL, et al
    Genome-Wide Meta-Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29511.
    PubMed     Abstract available


  100. CHUA MMJ, Blitz SE, Ng PR, Segar DJ, et al
    Focused Ultrasound Thalamotomy for Tremor in Parkinson's Disease: Outcomes in a Large, Prospective Cohort.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29569.
    PubMed     Abstract available


  101. TIAN Y, Ma G, Li H, Zeng Y, et al
    Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease.
    Mov Disord. 2023 Aug 3. doi: 10.1002/mds.29572.
    PubMed     Abstract available


  102. AQUINO C, Luo L, Agarwal P, Garg K, et al
    Deep Brain Stimulation as an Exclusion Criteria in Parkinson's Disease Studies: Time to Rethink?
    Mov Disord. 2023 Aug 2. doi: 10.1002/mds.29554.
    PubMed    


  103. VIRAMETEEKUL S, de Pablo-Fernandez E
    Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's Disease.
    Mov Disord. 2023;38:1574-1575.
    PubMed    


  104. GOETZ CG, Zou H, Stebbins GT, Schrag A, et al
    Reply to: Comment on "Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1564.
    PubMed    


  105. KOVACS N, Aschermann Z, Harmat M, Rohonczi M, et al
    Comment on "Summing MDS-UPDRS Parts 1 + 2 (Nonmotor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1563-1564.
    PubMed    


  106. BEACH TG, Adler CH, Shill HA, Zhang N, et al
    Accuracy of the Early Diagnosis of Parkinson's Disease.
    Mov Disord. 2023;38:1573-1574.
    PubMed    


  107. KLIETZ M, Mahmoudi N, Maudsley AA, Sheriff S, et al
    Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:1503-1514.
    PubMed     Abstract available


  108. AGIN-LIEBES J, Hickman RA, Vonsattel JP, Faust PL, et al
    Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations.
    Mov Disord. 2023;38:1541-1545.
    PubMed     Abstract available



  109. Abstracts of the 2023 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2023;38 Suppl 1:S1-S871.
    PubMed    


  110. ALBANESE A, Bhatia KP, Cardoso F, Comella C, et al
    Isolated Cervical Dystonia: Diagnosis and Classification.
    Mov Disord. 2023;38:1367-1378.
    PubMed     Abstract available


    July 2023
  111. LABRADOR-ESPINOSA MA, Silva-Rodriguez J, Reina-Castillo MI, Mir P, et al
    Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-beta Status in Parkinson's disease-Related Cognitive Decline.
    Mov Disord. 2023 Jul 26. doi: 10.1002/mds.29564.
    PubMed     Abstract available


  112. BORSCHE M, Berg D
    Blood-Based alpha-Synuclein Seeding-A New Era for Identifying Parkinsonian Syndromes.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29555.
    PubMed    


  113. JEONG SH, Kim SH, Park CW, Lee HS, et al
    Differential Implications of Cerebral Hypoperfusion and Hyperperfusion in Parkinson's Disease.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29565.
    PubMed     Abstract available


  114. LUTH T, Gabbert C, Koch S, Konig IR, et al
    Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
    Mov Disord. 2023 Jul 21. doi: 10.1002/mds.29563.
    PubMed     Abstract available


  115. LEAL TP, Rao SC, French-Kwawu JN, Gouveia MH, et al
    X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease.
    Mov Disord. 2023 Jul 20. doi: 10.1002/mds.29508.
    PubMed     Abstract available


  116. XYLAKI M, Chopra A, Weber S, Bartl M, et al
    Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Jul 14. doi: 10.1002/mds.29497.
    PubMed     Abstract available


  117. TESSON C, Bouchetara MS, Ferrien M, Lesage S, et al
    Identification of a DAGLB Mutation in a Non-Chinese Patient with Parkinson's Disease.
    Mov Disord. 2023 Jul 11. doi: 10.1002/mds.29533.
    PubMed    


  118. ZHUPARRIS A, Thijssen E, Elzinga WO, Makai-Boloni S, et al
    Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.
    Mov Disord. 2023 Jul 4. doi: 10.1002/mds.29520.
    PubMed     Abstract available


  119. ARSHAD U, Rahman F, Hanan N, Chen C, et al
    Longitudinal Meta-Analysis of Historical Parkinson's Disease Trials to Inform Future Trial Design.
    Mov Disord. 2023 Jul 3. doi: 10.1002/mds.29514.
    PubMed     Abstract available


  120. TURNER TH, Hinson VK
    Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2023;38:1125-1126.
    PubMed    


  121. PU J, Lin L, Jiang H, Hu Z, et al
    Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell-Derived A9 Dopaminergic Neurons.
    Mov Disord. 2023;38:1273-1281.
    PubMed     Abstract available


  122. ZOU H, Goetz CG, Stebbins GT, Schrag A, et al
    Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice.
    Mov Disord. 2023;38:1363-1364.
    PubMed    


    June 2023
  123. SCHLIESSER P, Struebing FL, Northoff BH, Kurz A, et al
    Detection of a Parkinson's Disease-Specific MicroRNA Signature in Nasal and Oral Swabs.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29515.
    PubMed     Abstract available


  124. VON BELOW D, Wallerstedt SM, Bergquist F
    Validation of the Swedish Patient-Reported Outcomes in Parkinson's Disease Scale in Outpatients.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29517.
    PubMed     Abstract available


  125. SENKEVICH K, Beletskaia M, Dworkind A, Yu E, et al
    Association of Rare Variants in ARSA with Parkinson's Disease.
    Mov Disord. 2023 Jun 28. doi: 10.1002/mds.29521.
    PubMed     Abstract available


  126. PAL G, Cook L, Schulze J, Verbrugge J, et al
    Genetic Testing in Parkinson's Disease.
    Mov Disord. 2023 Jun 27. doi: 10.1002/mds.29500.
    PubMed     Abstract available


  127. DIRKX MF, Shine JM, Helmich RC
    Integrative Brain States Facilitate the Expression of Parkinson's Tremor.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29506.
    PubMed     Abstract available


  128. VENUTO CS, Smith G, Herbst K, Zielinski R, et al
    Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29519.
    PubMed     Abstract available


  129. LIN CP, Knoop LEJ, Frigerio I, Bol JGJM, et al
    Nigral Pathology Contributes to Microstructural Integrity of Striatal and Frontal Tracts in Parkinson's Disease.
    Mov Disord. 2023 Jun 22. doi: 10.1002/mds.29510.
    PubMed     Abstract available


  130. SICILIANO M, De Micco R, Russo AG, Esposito F, et al
    Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29502.
    PubMed     Abstract available


  131. HAMEDANI AG, Auinger P, Willis AW, Safarpour D, et al
    Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29507.
    PubMed     Abstract available


  132. SIMONET C, Mahlknecht P, Marini K, Seppi K, et al
    The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29496.
    PubMed     Abstract available


  133. FLORES-TORRES MH, Bjornevik K, Hung AY, Healy BC, et al
    Subjective Cognitive Decline in Women with Features Suggestive of Prodromal Parkinson's Disease.
    Mov Disord. 2023 Jun 14. doi: 10.1002/mds.29503.
    PubMed     Abstract available


  134. YASSINE S, Gschwandtner U, Auffret M, Duprez J, et al
    Identification of Parkinson's Disease Subtypes from Resting-State Electroencephalography.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29451.
    PubMed     Abstract available


  135. SAUNDERS-PULLMAN R, Raymond D, Ortega RA, Shalash A, et al
    International Genetic Testing and Counseling Practices for Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29442.
    PubMed     Abstract available


  136. SCOTT GD, Neilson LE, Woltjer R, Quinn JF, et al
    Lifelong Association of Disorders Related to Military Trauma with Subsequent Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29457.
    PubMed     Abstract available


  137. GILES DORAN C, Wilson F, Goulding SR, Mazzocchi M, et al
    Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.
    Mov Disord. 2023;38:1115-1116.
    PubMed    


  138. WHONE A
    Reply to: "Bioinformatics and Immunohistochemistry Show Preserved Expression of GDNF Receptor RET in Parkinson's".
    Mov Disord. 2023;38:1117-1118.
    PubMed    


  139. PAL GD, David FJ, Shils JL, Munoz MJ, et al
    Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease.
    Mov Disord. 2023;38:1113-1114.
    PubMed    


  140. WEILL C, Gallant A, Baker Erdman H, Abu Snineh M, et al
    Reply to: "Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease".
    Mov Disord. 2023;38:1114.
    PubMed    


  141. NEUMANN WJ, Gilron R, Little S, Tinkhauser G, et al
    Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation.
    Mov Disord. 2023;38:937-948.
    PubMed     Abstract available


  142. MARTINO D, Karnik V, Bhidayasiri R, Hall DA, et al
    Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations.
    Mov Disord. 2023;38:1008-1026.
    PubMed     Abstract available


  143. SCHIDLITZKI A, Stanojlovic M, Fournier C, Kaufer C, et al
    Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing alpha-Synuclein.
    Mov Disord. 2023;38:1044-1055.
    PubMed     Abstract available


  144. STEFANI A, Serradell M, Holzknecht E, Gaig C, et al
    Low Specificity of Rapid Eye Movement Sleep Behavior Disorder Questionnaires: Need for Better Screening Methods.
    Mov Disord. 2023;38:1000-1007.
    PubMed     Abstract available


  145. UEDA J, Uemura N, Ishimoto T, Taguchi T, et al
    Ca(2+) -Calmodulin-Calcineurin Signaling Modulates alpha-Synuclein Transmission.
    Mov Disord. 2023;38:1056-1067.
    PubMed     Abstract available


  146. PEREZ-CARBONELL L, Simonet C, Chohan H, Gill A, et al
    The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure.
    Mov Disord. 2023;38:1089-1093.
    PubMed     Abstract available


  147. KUZKINA A, Panzer C, Seger A, Schmitt D, et al
    Dermal Real-Time Quaking-Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early alpha-Synucleinopathy.
    Mov Disord. 2023;38:1077-1082.
    PubMed     Abstract available


    May 2023
  148. PAYNE T, Appleby M, Buckley E, van Gelder LMA, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.
    Mov Disord. 2023 May 29. doi: 10.1002/mds.29450.
    PubMed     Abstract available


  149. GEORGIADES MJ, Shine JM, Gilat M, McMaster J, et al
    Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease.
    Mov Disord. 2023 May 25. doi: 10.1002/mds.29455.
    PubMed     Abstract available


  150. DOMEN CH, Sillau S, Liu Y, Adkins M, et al
    Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Delta9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29447.
    PubMed     Abstract available


  151. HUTTUNEN HJ, Booms S, Sjogren M, Kerstens V, et al
    Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29426.
    PubMed     Abstract available


  152. KROSCHE M, Kannenberg S, Butz M, Hartmann CJ, et al
    Slowing of Frontal beta Oscillations in Atypical Parkinsonism.
    Mov Disord. 2023 May 20. doi: 10.1002/mds.29378.
    PubMed     Abstract available


  153. DEN HEIJER JM, Kruithof AC, Moerland M, Walker M, et al
    A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
    Mov Disord. 2023 May 17. doi: 10.1002/mds.29346.
    PubMed     Abstract available


  154. RAFEE S, Fearon C
    Palmitoylation: A New Therapeutic Target for Parkinson's Disease?
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29418.
    PubMed    


  155. MAMARIL-DAVIS JC, Gelb AW, Larson PS
    Procedure-Related Complications in Sham Surgeries for Parkinson's Clinical Trials: A Meta-analysis.
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29406.
    PubMed     Abstract available


  156. SCHIRINZI T, Maftei D, Grillo P, Bovenzi R, et al
    Olfactory Neuron Substance P is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29433.
    PubMed    


  157. BROWN GC, Camacho M, Williams-Gray CH
    The Endotoxin Hypothesis of Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29432.
    PubMed     Abstract available


  158. RYMAN SG, Shaff N, Dodd A, Nitschke S, et al
    Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29429.
    PubMed     Abstract available


  159. OUTEIRO TF, Alcalay RN, Antonini A, Attems J, et al
    Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29419.
    PubMed     Abstract available


  160. KOROS C, Brockmann K, Simitsi AM, Bougea A, et al
    Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29399.
    PubMed    


  161. SENKEVICH K, Alipour P, Chernyavskaya E, Yu E, et al
    Potential Protective Link Between Type I Diabetes and Parkinson's Disease Risk and Progression.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29424.
    PubMed     Abstract available


  162. VALENTIJN PP, Eggers C, Bloem BR, Grimes D, et al
    Validation of the Rainbow Model of Integrated Care Measurement Tool in Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29413.
    PubMed     Abstract available


  163. NG J, Barral S, Waddington SN, Kurian MA, et al
    Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29416.
    PubMed     Abstract available


  164. JOST ST, Kaldenbach MA, Antonini A, Martinez-Martin P, et al
    Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29410.
    PubMed     Abstract available


  165. AVERNA A, Debove I, Nowacki A, Peterman K, et al
    Spectral Topography of the Subthalamic Nucleus to Inform Next-Generation Deep Brain Stimulation.
    Mov Disord. 2023;38:818-830.
    PubMed     Abstract available


  166. LOFREDI R, Scheller U, Mindermann A, Feldmann LK, et al
    Pallidal Beta Activity Is Linked to Stimulation-Induced Slowness in Dystonia.
    Mov Disord. 2023;38:894-899.
    PubMed     Abstract available


  167. ZHANG D, Shi Y, Yao J, Zhou L, et al
    Free-Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers.
    Mov Disord. 2023;38:764-773.
    PubMed     Abstract available


    April 2023
  168. MESTRE TA, McDermott MP, Lobo R, Ferreira JJ, et al
    The Lessebo Effect in Disease Modification Trials in Parkinson's Disease.
    Mov Disord. 2023 Apr 24. doi: 10.1002/mds.29414.
    PubMed     Abstract available


  169. GEROIN C, Artusi CA, Nonnekes J, Aquino C, et al
    Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management.
    Mov Disord. 2023 Apr 20. doi: 10.1002/mds.29377.
    PubMed    


  170. LI C, Lin J, Jiang Q, Yang T, et al
    Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29411.
    PubMed     Abstract available


  171. OH YS, Kim JS, Lyoo CH, Kim H, et al
    Obstructive Sleep Apnea and Striatal Dopamine Availability in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29402.
    PubMed     Abstract available


  172. BELOVA E, Semenova U, Gamaleya A, Tomskiy A, et al
    Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Apr 6. doi: 10.1002/mds.29393.
    PubMed     Abstract available


  173. MULLER T, Kuhn W
    Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
    Mov Disord. 2023;38:710-711.
    PubMed    


  174. THALER A, Mirelman A, Alcalay RN
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:713-714.
    PubMed    


  175. YANG X, Xiao Q
    Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".
    Mov Disord. 2023;38:711.
    PubMed    


  176. LANG AE
    Targeting alpha-Synuclein: A Further Viewpoint.
    Mov Disord. 2023;38:715-716.
    PubMed    


  177. POSTUMA RB, Lang AE
    The Clinical Diagnosis of Parkinson's Disease-We Are Getting Better.
    Mov Disord. 2023;38:515-517.
    PubMed    


  178. ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:714-715.
    PubMed    


  179. PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
    Reply to: "Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort".
    Mov Disord. 2023;38:709-710.
    PubMed    


  180. KRESOJEVIC N, Markovic V, Dobricic V, Stankovic I, et al
    Reply to: "Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism".
    Mov Disord. 2023;38:712-713.
    PubMed    


  181. LI C, Lin J, Jiang Q, Yang T, et al
    Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort.
    Mov Disord. 2023;38:708-709.
    PubMed    


  182. BOLOGNA M, Espay AJ, Fasano A, Paparella G, et al
    Redefining Bradykinesia.
    Mov Disord. 2023;38:551-557.
    PubMed    


  183. HUANG SY, Chen SF, Cui M, Zhao M, et al
    Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:676-682.
    PubMed     Abstract available


    March 2023
  184. BORSCHE M, Pratuseviciute N, Schaake S, Hinrichs F, et al
    The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity.
    Mov Disord. 2023 Mar 27. doi: 10.1002/mds.29385.
    PubMed    


  185. ZENG R, Wang J, Zheng C, Jiang R, et al
    Lack of Causal Associations of Inflammatory Bowel Disease with Parkinson's Disease and Other Neurodegenerative Disorders.
    Mov Disord. 2023 Mar 23. doi: 10.1002/mds.29386.
    PubMed     Abstract available


  186. ZHOU G, Ren J, Rong D, Zhou H, et al
    Monitoring Substantia Nigra Degeneration Using Free Water Imaging across Prodromal and Clinical Parkinson's Disease.
    Mov Disord. 2023 Mar 22. doi: 10.1002/mds.29366.
    PubMed     Abstract available


  187. MESTRE TA, Schlossmacher MG
    Target-Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe?
    Mov Disord. 2023 Mar 21. doi: 10.1002/mds.29382.
    PubMed    


  188. FLORES-TORRES MH, Christine CW, Bjornevik K, Molsberry SA, et al
    Long-Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men.
    Mov Disord. 2023 Mar 20. doi: 10.1002/mds.29383.
    PubMed     Abstract available


  189. DEN HEIJER JM, Cullen VC, Pereira DR, Yavuz Y, et al
    A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
    Mov Disord. 2023 Mar 14. doi: 10.1002/mds.29360.
    PubMed     Abstract available


  190. MUNOZ-DELGADO L, Labrador-Espinosa MA, Macias-Garcia D, Jesus S, et al
    Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease.
    Mov Disord. 2023 Mar 13. doi: 10.1002/mds.29369.
    PubMed     Abstract available


  191. KAMATH T, Macosko EZ
    Insights into Neurodegeneration in Parkinson's Disease from Single-Cell and Spatial Genomics.
    Mov Disord. 2023 Mar 7. doi: 10.1002/mds.29374.
    PubMed     Abstract available


  192. DORSEY ER, Ray A
    Paraquat, Parkinson's Disease, and Agnotology.
    Mov Disord. 2023 Mar 6. doi: 10.1002/mds.29371.
    PubMed    


  193. BLAUWENDRAAT C, Tayebi N, Woo EG, Lopez G, et al
    Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
    Mov Disord. 2023 Mar 3. doi: 10.1002/mds.29342.
    PubMed     Abstract available


  194. MARSILI L, Duque KR, Gregor N, Abdelghany E, et al
    Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases.
    Mov Disord. 2023;38:496-501.
    PubMed     Abstract available


  195. JENSEN PH, Schlossmacher MG, Stefanis L
    Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting alpha-Synuclein.
    Mov Disord. 2023;38:378-384.
    PubMed     Abstract available


  196. VIRAMETEEKUL S, Revesz T, Jaunmuktane Z, Warner TT, et al
    Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System Atrophy.
    Mov Disord. 2023;38:444-452.
    PubMed     Abstract available


  197. WANG EW, Brown GL, Lewis MM, Jellen LC, et al
    Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta.
    Mov Disord. 2023;38:464-473.
    PubMed     Abstract available


  198. TAN C, Nawaz H, Lageman SK, Cloud LJ, et al
    Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:474-479.
    PubMed     Abstract available


  199. WIEST C, Morgante F, Torrecillos F, Pogosyan A, et al
    Subthalamic Nucleus Stimulation-Induced Local Field Potential Changes in Dystonia.
    Mov Disord. 2023;38:423-434.
    PubMed     Abstract available


  200. ROSSI M, Hamed M, Rodriguez-Antiguedad J, Cornejo-Olivas M, et al
    Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review.
    Mov Disord. 2023;38:368-377.
    PubMed     Abstract available


    February 2023
  201. YACOUBIAN TA, Fang YD, Gerstenecker A, Amara A, et al
    Brain and Systemic Inflammation in De Novo Parkinson's Disease.
    Mov Disord. 2023 Feb 28. doi: 10.1002/mds.29363.
    PubMed     Abstract available


  202. EMMI A, Sandre M, Russo FP, Tombesi G, et al
    Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease.
    Mov Disord. 2023 Feb 27. doi: 10.1002/mds.29358.
    PubMed     Abstract available


  203. SCIACCA G, Mostile G, Disilvestro I, Donzuso G, et al
    Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
    Mov Disord. 2023 Feb 25. doi: 10.1002/mds.29344.
    PubMed     Abstract available


  204. JUNG JH, Na HK, Jeong SH, Chung SJ, et al
    Effects of Dihydropyridines on the Motor and Cognitive Outcomes of Patients with Parkinson's Disease.
    Mov Disord. 2023 Feb 24. doi: 10.1002/mds.29367.
    PubMed     Abstract available


  205. LANDELLE C, Dahlberg LS, Lungu O, Misic B, et al
    Altered Spinal Cord Functional Connectivity Associated with Parkinson's Disease Progression.
    Mov Disord. 2023 Feb 21. doi: 10.1002/mds.29354.
    PubMed     Abstract available


  206. MANCINI A, Stoops E, Demeyer L, Bellomo G, et al
    LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Mov Disord. 2023 Feb 18. doi: 10.1002/mds.29336.
    PubMed     Abstract available


  207. JENNINGS D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, et al
    LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
    Mov Disord. 2023 Feb 18. doi: 10.1002/mds.29297.
    PubMed     Abstract available


  208. SU D, Gan Y, Zhang Z, Cui Y, et al
    Multimodal Imaging of Substantia Nigra in Parkinson's Disease with Levodopa-Induced Dyskinesia.
    Mov Disord. 2023 Feb 17. doi: 10.1002/mds.29320.
    PubMed     Abstract available


  209. SUGIER PE, Lucotte EA, Domenighetti C, Law MH, et al
    Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers.
    Mov Disord. 2023 Feb 14. doi: 10.1002/mds.29337.
    PubMed     Abstract available


  210. NGUYEN TTH, Fournier A, Courtois E, Artaud F, et al
    Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study.
    Mov Disord. 2023 Feb 14. doi: 10.1002/mds.29349.
    PubMed     Abstract available


  211. AZIZ NA, Wullner U
    Genetic Variants in Sulfonylurea Targets Affect Parkinson's Disease Risk: A Two-Sample Mendelian Randomization Study.
    Mov Disord. 2023 Feb 13. doi: 10.1002/mds.29341.
    PubMed    


  212. CONCHA-MARAMBIO L, Weber S, Farris CM, Dakna M, et al
    Accurate Detection of alpha-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort.
    Mov Disord. 2023 Feb 13. doi: 10.1002/mds.29329.
    PubMed     Abstract available


  213. BECKER-COHEN M, Zimran A, Arkadir D, Revel-Vilk S, et al
    Has Parkinson Disease Gone to the Dogs?
    Mov Disord. 2023;38:358.
    PubMed    


  214. GAO CQ, Zhang XX, Wang MM, Guo JF, et al
    Reply to: Has Parkinson Disease Gone to the Dogs?
    Mov Disord. 2023;38:359.
    PubMed    


  215. GOETZ CG, Choi D, Guo Y, Stebbins GT, et al
    It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum.
    Mov Disord. 2023;38:342-347.
    PubMed     Abstract available


  216. GARRIDO A, Fairfoul G, Tolosa E, Marti MJ, et al
    Brain and Cerebrospinal Fluid alpha-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Mov Disord. 2023;38:333-338.
    PubMed     Abstract available


  217. OLSEN AL, Clemens SG, Feany MB
    Nicotine-Mediated Rescue of alpha-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.
    Mov Disord. 2023;38:244-255.
    PubMed     Abstract available


    January 2023
  218. FELDMANN LK, Lofredi R, Al-Fatly B, Busch JL, et al
    Christmas-Related Reduction in Beta Activity in Parkinson's Disease.
    Mov Disord. 2023 Jan 31. doi: 10.1002/mds.29334.
    PubMed     Abstract available


  219. STREUBEL-GALLASCH L, Seibler P
    Neuron-Derived Misfolded alpha-Synuclein in Blood: A Potential Biomarker for Parkinson's Disease?
    Mov Disord. 2023 Jan 31. doi: 10.1002/mds.29331.
    PubMed    


  220. BORSCHE M, Martens A, Hormann P, Bruckmann T, et al
    In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN-Related Parkinson's Disease.
    Mov Disord. 2023 Jan 30. doi: 10.1002/mds.29333.
    PubMed     Abstract available


  221. KIM J, Inbo H, Kim HS, Kim W, et al
    First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells.
    Mov Disord. 2023 Jan 24. doi: 10.1002/mds.29316.
    PubMed     Abstract available


  222. VOLLSTEDT EJ, Schaake S, Lohmann K, Padmanabhan S, et al
    Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort.
    Mov Disord. 2023 Jan 24. doi: 10.1002/mds.29288.
    PubMed     Abstract available


  223. BOKTOR JC, Sharon G, Verhagen Metman LA, Hall DA, et al
    Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome.
    Mov Disord. 2023 Jan 24. doi: 10.1002/mds.29300.
    PubMed     Abstract available


  224. KAASINEN V, Luo S, Martinez-Martin P, Goetz CG, et al
    Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease.
    Mov Disord. 2023 Jan 20. doi: 10.1002/mds.29335.
    PubMed     Abstract available


  225. WEILL C, Gallant A, Baker Erdman H, Abu Snineh M, et al
    The Genetic Etiology of Parkinson's Disease Does Not Robustly Affect Subthalamic Physiology.
    Mov Disord. 2023 Jan 9. doi: 10.1002/mds.29310.
    PubMed     Abstract available


  226. GUO Y, Goetz CG, Stebbins GT, Mestre TA, et al
    Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.
    Mov Disord. 2023 Jan 9. doi: 10.1002/mds.29308.
    PubMed     Abstract available


  227. ABDELHAFEEZ M, Elsayed I
    In Situ Global Structural Proteome Analysis Identifies Potential Biomarkers for Parkinson's Disease.
    Mov Disord. 2023 Jan 9. doi: 10.1002/mds.29315.
    PubMed    


  228. VIRAMETEEKUL S, Revesz T, Jaunmuktane Z, Warner TT, et al
    Clinical Diagnostic Accuracy of Parkinson's Disease: Where Do We Stand?
    Mov Disord. 2023 Jan 5. doi: 10.1002/mds.29317.
    PubMed     Abstract available


  229. PARLAR SC, Grenn FP, Kim JJ, Baluwendraat C, et al
    Classification of GBA1 Variants in Parkinson's Disease: The GBA1-PD Browser.
    Mov Disord. 2023 Jan 4. doi: 10.1002/mds.29314.
    PubMed     Abstract available


  230. NOBILEAU A, Gaurav R, Chougar L, Faucher A, et al
    Neuromelanin-Sensitive Magnetic Resonance Imaging Changes in the Locus Coeruleus/Subcoeruleus Complex in Patients with Typical and Atypical Parkinsonism.
    Mov Disord. 2023 Jan 2. doi: 10.1002/mds.29309.
    PubMed     Abstract available


  231. LLOYD K, Lawton M, Whone A
    Practically Defined Off-State Dyskinesia Following Repeated Intraputamenal Glial Cell Line-Derived Neurotrophic Factor Administration.
    Mov Disord. 2023;38:104-112.
    PubMed     Abstract available


  232. BRINK-KJAER A, Gupta N, Marin E, Zitser J, et al
    Ambulatory Detection of Isolated Rapid-Eye-Movement Sleep Behavior Disorder Combining Actigraphy and Questionnaire.
    Mov Disord. 2023;38:82-91.
    PubMed     Abstract available


  233. ZHANG D, Zhou L, Shi Y, Liu J, et al
    Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers.
    Mov Disord. 2023;38:138-142.
    PubMed     Abstract available


  234. MATTIOLI P, Orso B, Liguori C, Fama F, et al
    Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder.
    Mov Disord. 2023;38:57-67.
    PubMed     Abstract available


    December 2022
  235. CULLINANE PW, de Pablo Fernandez E, Konig A, Outeiro TF, et al
    Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.
    Mov Disord. 2022 Dec 26. doi: 10.1002/mds.29298.
    PubMed     Abstract available


  236. BAIK K, Kim HR, Park M, Lee Y, et al
    Effect of Amyloid on Cognitive Performance in Parkinson's Disease and Dementia with Lewy Bodies.
    Mov Disord. 2022 Dec 17. doi: 10.1002/mds.29295.
    PubMed     Abstract available


  237. PALERMO G, Ceravolo R
    Clues to Reshaping Anti-alpha-Synuclein Immunotherapy in Early Parkinson's Disease Patients.
    Mov Disord. 2022 Dec 15. doi: 10.1002/mds.29294.
    PubMed    


  238. NILSSON J, Constantinescu J, Nellgard B, Jakobsson P, et al
    Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction Are Altered in Parkinson's Disease and Related Disorders.
    Mov Disord. 2022 Dec 12. doi: 10.1002/mds.29287.
    PubMed     Abstract available


  239. PINTO S, Nebel A, Rau J, Espesser R, et al
    Results of a Randomized Clinical Trial of Speech after Early Neurostimulation in Parkinson's Disease.
    Mov Disord. 2022 Dec 3. doi: 10.1002/mds.29282.
    PubMed     Abstract available


  240. RUSSO MJ, MacLeod K, Lamoureux J, Lebovitz R, et al
    Aggregation-Seeding Forms of alpha-Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid.
    Mov Disord. 2022;37:2462-2463.
    PubMed    


  241. LORENZO-BETANCOR O, Galosi L, Bonfili L, Eleuteri AM, et al
    Homozygous CADPS2 Mutations Cause Neurodegenerative Disease with Lewy Body-like Pathology in Parrots.
    Mov Disord. 2022;37:2345-2354.
    PubMed     Abstract available


    November 2022
  242. DARMANI G, Drummond NM, Ramezanpour H, Saha U, et al
    Long-Term Recording of Subthalamic Aperiodic Activities and Beta Bursts in Parkinson's Disease.
    Mov Disord. 2022 Nov 24. doi: 10.1002/mds.29276.
    PubMed     Abstract available


  243. TALEBI AH, Ypinga JHL, De Vries NM, Nonnekes J, et al
    Specialized Versus Generic Allied Health Therapy and the Risk of Parkinson's Disease Complications.
    Mov Disord. 2022 Nov 24. doi: 10.1002/mds.29274.
    PubMed     Abstract available


  244. TANG Y, Li L, Hu T, Jiao F, et al
    In Vivo (18) F-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia.
    Mov Disord. 2022 Nov 11. doi: 10.1002/mds.29273.
    PubMed     Abstract available


  245. KRAINC T, Monje MHG, Kinsinger M, Bustos BI, et al
    Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
    Mov Disord. 2022 Nov 9. doi: 10.1002/mds.29260.
    PubMed     Abstract available


  246. LEDONNE A, Massaro Cenere M, Paldino E, D'Angelo V, et al
    Morpho-Functional Changes of Nigral Dopamine Neurons in an alpha-Synuclein Model of Parkinson's Disease.
    Mov Disord. 2022 Nov 9. doi: 10.1002/mds.29269.
    PubMed     Abstract available


  247. HOENIG MC, Dzialas V, Drzezga A, van Eimeren T, et al
    The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?
    Mov Disord. 2022 Nov 7. doi: 10.1002/mds.29266.
    PubMed    


  248. TROCHE MS, Curtis JA, Sevitz JS, Dakin AE, et al
    Rehabilitating Cough Dysfunction in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2022 Nov 7. doi: 10.1002/mds.29268.
    PubMed     Abstract available


  249. PIZARRO GALLEGUILLOS BM, Mohamed W, Perinan MT
    The Glycoprotein GPNMB: A Secret Ingredient for Understanding Parkinson's Disease Etiology?
    Mov Disord. 2022 Nov 2. doi: 10.1002/mds.29264.
    PubMed    


  250. BOHNEN NI, Kanel P, van Emde Boas M, Roytman S, et al
    Vestibular Sensory Conflict During Postural Control, Freezing of Gait, and Falls in Parkinson's Disease.
    Mov Disord. 2022;37:2257-2262.
    PubMed     Abstract available


  251. PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
    Reply to: No Association between Rare TWNK Variants and Parkinson's Disease in European Cohorts.
    Mov Disord. 2022;37:2319-2320.
    PubMed    


  252. SOTIRAKIS C, Conway N, Su Z, Villarroel M, et al
    Longitudinal Monitoring of Progressive Supranuclear Palsy using Body-Worn Movement Sensors.
    Mov Disord. 2022;37:2263-2271.
    PubMed     Abstract available


  253. LEYS F, Eschlbock S, Campese N, Mahlknecht P, et al
    Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?
    Mov Disord. 2022;37:2310-2312.
    PubMed    


    October 2022
  254. BARTL M, Dakna M, Schade S, Otte B, et al
    Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease.
    Mov Disord. 2022 Oct 20. doi: 10.1002/mds.29257.
    PubMed     Abstract available


  255. VIVACQUA G, Mason M, De Bartolo MI, Wegrzynowicz M, et al
    Salivary alpha-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson's Disease.
    Mov Disord. 2022 Oct 19. doi: 10.1002/mds.29246.
    PubMed    


  256. HULZINGA F, Seuthe J, D'Cruz N, Ginis P, et al
    Split-Belt Treadmill Training to Improve Gait Adaptation in Parkinson's Disease.
    Mov Disord. 2022 Oct 14. doi: 10.1002/mds.29238.
    PubMed     Abstract available


  257. CLERET DE LANGAVANT L, Roze E, Petit A, Tressieres B, et al
    Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism.
    Mov Disord. 2022 Oct 10. doi: 10.1002/mds.29222.
    PubMed     Abstract available


  258. ZIMPRICH A
    LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?
    Mov Disord. 2022 Oct 5. doi: 10.1002/mds.29243.
    PubMed    


  259. KIM R, Kim H, Kim YK, Yoon EJ, et al
    Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease.
    Mov Disord. 2022;37:2099-2109.
    PubMed     Abstract available


  260. SAWAMURA M, Onoe H, Tsukada H, Isa K, et al
    Lewy Body Disease Primate Model with alpha-Synuclein Propagation from the Olfactory Bulb.
    Mov Disord. 2022;37:2033-2044.
    PubMed     Abstract available


  261. SOTO M, Iranzo A, Lahoz S, Fernandez M, et al
    Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases.
    Mov Disord. 2022;37:2086-2098.
    PubMed     Abstract available


    September 2022
  262. DANG X, Zhang Z, Luo XJ
    Mendelian Randomization Study Using Dopaminergic Neuron-Specific eQTL Nominates Potential Causal Genes for Parkinson's Disease.
    Mov Disord. 2022 Sep 29. doi: 10.1002/mds.29239.
    PubMed     Abstract available


  263. PAULY C, Glaab E, Hansen M, Martin-Gallausiaux C, et al
    Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease.
    Mov Disord. 2022 Sep 23. doi: 10.1002/mds.29212.
    PubMed    


  264. WILHELM E, Quoilin C, Derosiere G, Paco S, et al
    Corticospinal Suppression Underlying Intact Movement Preparation Fades in Parkinson's Disease.
    Mov Disord. 2022 Sep 19. doi: 10.1002/mds.29214.
    PubMed     Abstract available


  265. CHOU KL, Dayalu P, Koeppe RA, Gilman S, et al
    Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
    Mov Disord. 2022 Sep 14. doi: 10.1002/mds.29220.
    PubMed     Abstract available


  266. MILLS KA, Pontone GM
    The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?
    Mov Disord. 2022 Sep 14. doi: 10.1002/mds.29224.
    PubMed    


  267. MENG Y, Pople CB, Huang Y, Jones RM, et al
    Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance-Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study.
    Mov Disord. 2022 Sep 11. doi: 10.1002/mds.29190.
    PubMed     Abstract available


  268. LANSBURY P
    The Sphingolipids Clearly Play a Role in Parkinson's Disease, but Nature Has Made it Complicated.
    Mov Disord. 2022 Sep 10. doi: 10.1002/mds.29204.
    PubMed    


  269. LUO J, Wu H, Li J, Xian W, et al
    Joint Modeling Study Identifies Blood-Based Transcripts Link to Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2022 Sep 10. doi: 10.1002/mds.29213.
    PubMed     Abstract available


  270. ZHANG X, Xu J, Liu Y, Chen S, et al
    Diet Quality is Associated with Prodromal Parkinson's Disease Features in Chinese Adults.
    Mov Disord. 2022 Sep 7. doi: 10.1002/mds.29208.
    PubMed     Abstract available


  271. SENKEVICH K, Gan-Or Z
    No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts.
    Mov Disord. 2022 Sep 4. doi: 10.1002/mds.29216.
    PubMed    


  272. SEIFAR F, Dinasarapu AR, Jinnah HA
    Uric Acid in Parkinson's Disease: What Is the Connection?
    Mov Disord. 2022 Sep 3. doi: 10.1002/mds.29209.
    PubMed     Abstract available


  273. HARIZ M, Bronstein JM, Cosgrove GR, de Bie RMA, et al
    European Academy of Neurology/Movement Disorder Society-European Section Guidelines on Pallidotomy for Parkinson's Disease: Let's Be Accurate.
    Mov Disord. 2022 Sep 1. doi: 10.1002/mds.29210.
    PubMed    


    August 2022
  274. FERREIRA JJ, Poewe W, Rascol O, Stocchi F, et al
    Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
    Mov Disord. 2022 Aug 31. doi: 10.1002/mds.29193.
    PubMed     Abstract available


  275. COURTOIS E, Nguyen TTH, Fournier A, Carcaillon-Bentata L, et al
    Identifying Protective Drugs for Parkinson's Disease in Health-Care Databases Using Machine Learning.
    Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29205.
    PubMed     Abstract available


  276. LI D, Mastaglia FL, Yau WY, Chen S, et al
    Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?
    Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29201.
    PubMed    


  277. GOLFRE ANDREASI N, Cilia R, Romito LM, Bonvegna S, et al
    Magnetic Resonance-Guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early-Stage Tremor-Dominant Parkinson's Disease: A Pilot Study.
    Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29200.
    PubMed     Abstract available


  278. ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2022 Aug 27. doi: 10.1002/mds.29197.
    PubMed     Abstract available


  279. GAO CQ, Wang SN, Wang MM, Li JJ, et al
    Sensitivity of Sniffer Dogs for a Diagnosis of Parkinson's Disease: A Diagnostic Accuracy Study.
    Mov Disord. 2022 Aug 25. doi: 10.1002/mds.29180.
    PubMed     Abstract available


  280. RUS T, Schindlbeck KA, Tang CC, Vo A, et al
    Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease.
    Mov Disord. 2022 Aug 23. doi: 10.1002/mds.29188.
    PubMed     Abstract available


  281. SIMMERING JE, Welsh MJ, Schultz J, Narayanan NS, et al
    Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease.
    Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29184.
    PubMed     Abstract available


  282. STEFANO DP, Franciotti R, Chiacchiaretta P, Ferretti A, et al
    Altered Medial Prefrontal Connectivity in Parkinson's Disease Patients with Somatic Symptoms.
    Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29187.
    PubMed     Abstract available


  283. YUAN X, Yang Y, Liu C, Tian Y, et al
    Fine Particulate Matter Triggers alpha-Synuclein Fibrillization and Parkinson-like Neurodegeneration.
    Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29181.
    PubMed     Abstract available


  284. REYES CJ, Asano K, Todd PK, Klein C, et al
    Repeat-Associated Non-AUG Translation of AGAGGG Repeats that Cause X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2022 Aug 16. doi: 10.1002/mds.29183.
    PubMed     Abstract available


  285. SAFARPOUR D, Brumbach BH, Arena M, Quinn J, et al
    Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study.
    Mov Disord. 2022 Aug 15. doi: 10.1002/mds.29176.
    PubMed     Abstract available


  286. SMIT JW, Basile P, Prato MK, Detalle L, et al
    Phase 1/1b Studies of UCB0599, an Oral Inhibitor of alpha-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.
    Mov Disord. 2022 Aug 12. doi: 10.1002/mds.29170.
    PubMed     Abstract available


  287. BANWINKLER M, Dzialas V, Hoenig MC, van Eimeren T, et al
    Gray Matter Volume Loss in Proposed Brain-First and Body-First Parkinson's Disease Subtypes.
    Mov Disord. 2022 Aug 9. doi: 10.1002/mds.29172.
    PubMed     Abstract available


  288. MCKEE KE, Gilbert RM, Spigle WA, Tilley BC, et al
    Inclusion of Non-English-Speaking Participants in Studies of Parkinson's Disease: A Call to Action.
    Mov Disord. 2022 Aug 5. doi: 10.1002/mds.29179.
    PubMed    


  289. TANG X, Gonzalez-Latapi P, Marras C, Visanji NP, et al
    Epigenetic Clock Acceleration Is Linked to Age at Onset of Parkinson's Disease.
    Mov Disord. 2022 Aug 3. doi: 10.1002/mds.29157.
    PubMed     Abstract available


  290. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Reply to: "Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations"?
    Mov Disord. 2022;37:1782.
    PubMed    


  291. GLEASON AM, Tayebi N, Lopez GJ, Sidransky E, et al
    Reply to: "Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1-Associated Parkinson's Disease".
    Mov Disord. 2022;37:1781-1782.
    PubMed    


  292. LI C, Lin J, Gu X, Hou Y, et al
    Mutation Screening of TFG in alpha-Synucleinopathy and Amyotrophic Lateral Sclerosis.
    Mov Disord. 2022;37:1756-1761.
    PubMed     Abstract available


  293. PAZ RM, Stahl AM, Rela L, Murer MG, et al
    D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
    Mov Disord. 2022;37:1693-1706.
    PubMed     Abstract available


    July 2022
  294. DAIDA K, Shimonaka S, Shiba-Fukushima K, Ogata J, et al
    alpha-Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid-Binding Property.
    Mov Disord. 2022 Jul 27. doi: 10.1002/mds.29162.
    PubMed     Abstract available


  295. TE VRUCHTE D, Sturchio A, Priestman DA, Tsitsi P, et al
    Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels.
    Mov Disord. 2022 Jul 25. doi: 10.1002/mds.29163.
    PubMed     Abstract available


  296. SCHUMACHER-SCHUH AF, Bieger A, Okunoye O, Mok KY, et al
    Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions.
    Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29126.
    PubMed     Abstract available


  297. RAJAN R, Garg K, Srivastava AK, Singh M, et al
    Device-Assisted and Neuromodulatory Therapies for Parkinson's Disease: A Network Meta-Analysis.
    Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29160.
    PubMed     Abstract available


  298. BILLINGSLEY KJ, Alvarez Jerez P, Grenn FP, Bandres-Ciga S, et al
    Profiling the NOTCH2NLC GGC Repeat Expansion in Parkinson's Disease in the European Population.
    Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29155.
    PubMed    


  299. LIU FT, Li XY, Lu JY, Wu P, et al
    (18) F-Florzolotau Tau Positron Emission Tomography Imaging in Patients with Multiple System Atrophy-Parkinsonian Subtype.
    Mov Disord. 2022 Jul 21. doi: 10.1002/mds.29159.
    PubMed     Abstract available


  300. MARANO M, Anzini G, Musumeci G, Magliozzi A, et al
    Transcutaneous Auricular Vagus Stimulation Improves Gait and Reaction Time in Parkinson's Disease.
    Mov Disord. 2022 Jul 21. doi: 10.1002/mds.29166.
    PubMed    


  301. ILIEVA NM, De Miranda BR
    Rest and Digest-The Basal Role of Autophagy in Neurons and Its Relevance to Parkinson's Disease.
    Mov Disord. 2022 Jul 20. doi: 10.1002/mds.29165.
    PubMed    


  302. LU J, Ge J, Chen K, Sun Y, et al
    Consistent Abnormalities in Metabolic Patterns of Lewy Body Dementias.
    Mov Disord. 2022 Jul 20. doi: 10.1002/mds.29138.
    PubMed     Abstract available


  303. PEREZ-OLIVEIRA S, Alvarez I, Rosas I, Menendez-Gonzalez M, et al
    Intermediate and Expanded HTT Alleles and the Risk for alpha-Synucleinopathies.
    Mov Disord. 2022 Jul 19. doi: 10.1002/mds.29153.
    PubMed     Abstract available


  304. LUO S, Zou H, Stebbins GT, Schwarzschild MA, et al
    Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.
    Mov Disord. 2022 Jul 16. doi: 10.1002/mds.29154.
    PubMed     Abstract available


  305. DELVA A, Van Laere K, Vandenberghe W
    Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease.
    Mov Disord. 2022 Jul 12. doi: 10.1002/mds.29148.
    PubMed     Abstract available


  306. DOMENIGHETTI C, Douillard V, Sugier PE, Sreelatha AAK, et al
    The Interaction between HLA-DRB1 and Smoking in Parkinson's Disease Revisited.
    Mov Disord. 2022 Jul 10. doi: 10.1002/mds.29133.
    PubMed     Abstract available


  307. SUBERT M, Simek M, Novotny M, Tykalova T, et al
    Linguistic Abnormalities in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2022 Jul 7. doi: 10.1002/mds.29140.
    PubMed     Abstract available


  308. PERCETTI M, Franco G, Monfrini E, Caporali L, et al
    TWNK in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study.
    Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29139.
    PubMed     Abstract available


  309. KOPYTOVA AE, Usenko TS, Baydakova GV, Nikolaev MA, et al
    Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations?
    Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29132.
    PubMed    


  310. DEUSCHL G, Antonini A, Costa J, Smilowska K, et al
    European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.
    Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29066.
    PubMed     Abstract available


  311. VIJIARATNAM N, Lawton M, Real R, Heslegrave AJ, et al
    Diabetes and Neuroaxonal Damage in Parkinson's Disease.
    Mov Disord. 2022;37:1568-1569.
    PubMed    


  312. BUHMANN C, Potter-Nerger M, Schulz R, Gerloff C, et al
    Reply to: "Diabetes and Neuroaxonal Damage in Parkinson's Disease".
    Mov Disord. 2022;37:1569-1570.
    PubMed    


  313. COCHEN DE COCK V, Dotov D, Damm L, Janaqi S, et al
    Reply to: "Is Gait Dysfunction Prominent Sign of Isolated Rapid Eye Movement Sleep Behavior Disorder?"
    Mov Disord. 2022;37:1576-1577.
    PubMed    


  314. KLARENDIC M, Kojovic M
    Reply to: "Neither Friend Nor Foe: Beekeeping and Parkinson's Disease".
    Mov Disord. 2022;37:1575.
    PubMed    


  315. NETUKOVA S, Rusz J, Ruzicka E, Krupicka R, et al
    Is Gait Dysfunction a Prominent Sign of Isolated Rapid Eye Movement Sleep Behavior Disorder?
    Mov Disord. 2022;37:1575-1576.
    PubMed    


  316. WASNER K, Smajic S, Ghelfi J, Delcambre S, et al
    Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation.
    Mov Disord. 2022;37:1405-1415.
    PubMed     Abstract available


  317. YU HJ, Thijssen E, van Brummelen E, van der Plas JL, et al
    A Randomized First-in-Human Study With UB-312, a UBITh(R) alpha-Synuclein Peptide Vaccine.
    Mov Disord. 2022;37:1416-1424.
    PubMed     Abstract available


  318. TAYLOR NL, Wainstein G, Quek D, Lewis SJG, et al
    The Contribution of Noradrenergic Activity to Anxiety-Induced Freezing of Gait.
    Mov Disord. 2022;37:1432-1443.
    PubMed     Abstract available


    June 2022
  319. LABANDEIRA-GARCIA JL, Parga JA
    Nigral Neurons Degenerating in Parkinson's Disease Express the Angiotensin Receptor Type 1 Gene.
    Mov Disord. 2022 Jun 29. doi: 10.1002/mds.29137.
    PubMed     Abstract available


  320. PINEDA-PARDO JA, Gasca-Salas C, Fernandez-Rodriguez B, Rodriguez-Rojas R, et al
    Striatal Blood-Brain Barrier Opening in Parkinson's Disease Dementia: A Pilot Exploratory Study.
    Mov Disord. 2022 Jun 28. doi: 10.1002/mds.29134.
    PubMed     Abstract available


  321. POHL EDR, Upadhyay N, Kobeleva X, Purrer V, et al
    Coherent Structural and Functional Network Changes after Thalamic Lesions in Essential Tremor.
    Mov Disord. 2022 Jun 23. doi: 10.1002/mds.29130.
    PubMed     Abstract available


  322. WANG P, Pan J, Luo Q, Chen J, et al
    A 10-Year Community-Based Study of Leucine-Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease.
    Mov Disord. 2022 Jun 22. doi: 10.1002/mds.29127.
    PubMed     Abstract available


  323. STRAKA I, Svantnerova J, Minar M, Stankova S, et al
    Neurodevelopmental Gene-Related Dystonia-Parkinsonism with Onset in Adults: A Case with NAA15 Variant.
    Mov Disord. 2022 Jun 22. doi: 10.1002/mds.29125.
    PubMed    


  324. XIE A, Ensink E, Li P, Gordevicius J, et al
    Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms.
    Mov Disord. 2022 Jun 20. doi: 10.1002/mds.29128.
    PubMed     Abstract available


  325. LUO S, Goetz CG, Choi D, Aggarwal S, et al
    Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine.
    Mov Disord. 2022 Jun 18. doi: 10.1002/mds.29129.
    PubMed     Abstract available


  326. COKU I, Mutez E, Eddarkaoui S, Carrier S, et al
    Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.
    Mov Disord. 2022 Jun 16. doi: 10.1002/mds.29124.
    PubMed     Abstract available


  327. OLSON JW, Nakhmani A, Irwin ZT, Edwards LJ, et al
    Cortical and Subthalamic Nucleus Spectral Changes During Limb Movements in Parkinson's Disease Patients with and Without Dystonia.
    Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29057.
    PubMed     Abstract available


  328. ATHAUDA D, Evans J, Wernick A, Virdi G, et al
    The Impact of Type 2 Diabetes in Parkinson's Disease.
    Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29122.
    PubMed     Abstract available


  329. AJALIN RM, Al-Abdulrasul H, Tuisku JM, Hirvonen JES, et al
    Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [(18) F]FMPEP-d2.
    Mov Disord. 2022 Jun 8. doi: 10.1002/mds.29117.
    PubMed     Abstract available


  330. RINNE JO, Jucaite A, Cselenyi Z, Farde L, et al
    Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy.
    Mov Disord. 2022 Jun 6. doi: 10.1002/mds.29078.
    PubMed    



  331. The PSG 32nd Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders.
    Mov Disord. 2022;37 Suppl 1:S1-S36.
    PubMed    


  332. SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
    Reply to: "Risk Disclosure in Prodromal Parkinson's Disease".
    Mov Disord. 2022;37:1327.
    PubMed    


  333. MORRIS LA, O'Callaghan C, Le Heron C
    Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease.
    Mov Disord. 2022;37:1149-1163.
    PubMed     Abstract available


    May 2022
  334. HOBSON DE, Del Bigio MR
    Beekeeper Parkinsonism.
    Mov Disord. 2022 May 31. doi: 10.1002/mds.29076.
    PubMed    


  335. LI C, Hou Y, Ou R, Gu X, et al
    Genetic Determinants of Survival in Parkinson's Disease in the Asian Population.
    Mov Disord. 2022 May 26. doi: 10.1002/mds.29069.
    PubMed     Abstract available


  336. DU G, Wang E, Sica C, Chen H, et al
    Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage.
    Mov Disord. 2022 May 25. doi: 10.1002/mds.29062.
    PubMed     Abstract available


  337. YANG X, Ai P, He X, Mo C, et al
    Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids.
    Mov Disord. 2022 May 24. doi: 10.1002/mds.29063.
    PubMed     Abstract available


  338. KIM R, Kim HJ, Shin JH, Lee CY, et al
    Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson's Disease.
    Mov Disord. 2022 May 21. doi: 10.1002/mds.29056.
    PubMed     Abstract available


  339. SMEYNE RJ, Eells JB, Chatterjee D, Byrne M, et al
    COVID-19 infection enhances susceptibility to oxidative-stress induced parkinsonism.
    Mov Disord. 2022 May 17. doi: 10.1002/mds.29116.
    PubMed     Abstract available


  340. YE R, O'Callaghan C, Rua C, Hezemans FH, et al
    Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders.
    Mov Disord. 2022 May 16. doi: 10.1002/mds.29072.
    PubMed     Abstract available


  341. MAHLKNECHT P, Foltynie T, Limousin P, Poewe W, et al
    How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
    Mov Disord. 2022 May 12. doi: 10.1002/mds.29052.
    PubMed     Abstract available


  342. YAMASHITA R, Beck G, Yonenobu Y, Inoue K, et al
    TDP-43 Proteinopathy Presenting with Typical Symptoms of Parkinson's Disease.
    Mov Disord. 2022 May 9. doi: 10.1002/mds.29048.
    PubMed     Abstract available


  343. SOSSI V, Patterson JR, McCormick S, Kemp CJ, et al
    Dopaminergic Positron Emission Tomography Imaging in the Alpha-Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease.
    Mov Disord. 2022 May 7. doi: 10.1002/mds.29051.
    PubMed     Abstract available


  344. WANG S, Unnithan S, Bryant N, Chang A, et al
    Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29043.
    PubMed     Abstract available


  345. PAN Y, Xue J, Chen J, Zhang X, et al
    Assessment of GGC Repeat Expansion in GIPC1 in Patients with Parkinson's Disease.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29041.
    PubMed    


  346. FILIPPI M, Balestrino R, Basaia S, Agosta F, et al
    Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29047.
    PubMed     Abstract available


  347. ZHOU X, Liu Z, Zhou X, Xiang Y, et al
    The Chinese Parkinson's Disease Registry (CPDR): Study Design and Baseline Patient Characteristics.
    Mov Disord. 2022 May 3. doi: 10.1002/mds.29037.
    PubMed     Abstract available


  348. STEINHARDT J, Hanssen H, Heldmann M, Sprenger A, et al
    Prodromal X-Linked Dystonia-Parkinsonism is Characterized by a Subclinical Motor Phenotype.
    Mov Disord. 2022 May 2. doi: 10.1002/mds.29033.
    PubMed     Abstract available


  349. MACIAS-GARCIA D, Perinan MT, Munoz-Delgado L, Jesus S, et al
    Reply to: "Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations".
    Mov Disord. 2022;37:1119-1120.
    PubMed    


  350. GRISANTI S, Ferri L, Cavallieri F, Fioravanti V, et al
    Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Mov Disord. 2022;37:1117-1118.
    PubMed    


  351. LAANSMA MA, Bright JK, Jahanshad N, Thompson PM, et al
    Reply to: "Parkinson's Disease, Premature Mortality, and Amygdala".
    Mov Disord. 2022;37:1111-1112.
    PubMed    


  352. RAO SC, Pattipati S, Salim A, Gutierrez N, et al
    Promoting Gender Inclusivity: A Questionnaire for Women's Health Factors in Parkinson's Disease.
    Mov Disord. 2022;37:1112-1113.
    PubMed    


  353. SCORZA FA, de Almeida AG, Scorza CA, Finsterer J, et al
    Parkinson's Disease, Premature Mortality, and Amygdala.
    Mov Disord. 2022;37:1110-1111.
    PubMed    


  354. DARWEESH SKL, Vermeulen R, Bloem BR, Peters S, et al
    Exposure to Pesticides Predicts Prodromal Feature of Parkinson's Disease: Public Health Implications.
    Mov Disord. 2022;37:883-885.
    PubMed    


  355. SUBRAMANIAN I, Mathur S, Oosterbaan A, Flanagan R, et al
    Reply to: "Promoting Gender Inclusivity: A questionnaire for Women's Health Factors in Parkinson's Disease".
    Mov Disord. 2022;37:1113.
    PubMed    


  356. FOFFANI G
    An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis.
    Mov Disord. 2022;37:1105-1106.
    PubMed    


  357. ALZGHOOL OM, van Dongen G, van de Giessen E, Schoonmade L, et al
    alpha-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.
    Mov Disord. 2022;37:936-948.
    PubMed     Abstract available


  358. GANAPATHY S R, Levova K, Kotackova L, Trnka J, et al
    Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2022;37:983-992.
    PubMed     Abstract available


  359. TODISCO M, Cosentino G, Scardina S, Fresia M, et al
    Diagnostic and Prognostic Value of External Anal Sphincter EMG Patterns in Multiple System Atrophy.
    Mov Disord. 2022;37:1069-1074.
    PubMed     Abstract available


  360. GAURAV R, Pyatigorskaya N, Biondetti E, Valabregue R, et al
    Deep Learning-Based Neuromelanin MRI Changes of Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2022;37:1064-1069.
    PubMed     Abstract available


    April 2022
  361. BANDRES-CIGA S
    Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics.
    Mov Disord. 2022 Apr 30. doi: 10.1002/mds.29042.
    PubMed    


  362. TANIMURA A, Shen W, Wokosin D, Surmeier DJ, et al
    Pathway-Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2022 Apr 29. doi: 10.1002/mds.29030.
    PubMed     Abstract available


  363. KARAGIANIS JL
    Re: Risk Disclosure in Prodromal Parkinson's Disease.
    Mov Disord. 2022 Apr 28. doi: 10.1002/mds.29038.
    PubMed    


  364. LANGE LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, et al
    Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.
    Mov Disord. 2022 Apr 28. doi: 10.1002/mds.28982.
    PubMed     Abstract available


  365. KOLMANCIC K, Zupancic NK, Trost M, Flisar D, et al
    Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.
    Mov Disord. 2022 Apr 18. doi: 10.1002/mds.29028.
    PubMed     Abstract available


  366. YASSINE S, Gschwandtner U, Auffret M, Achard S, et al
    Functional Brain Dysconnectivity in Parkinson's Disease: A 5-Year Longitudinal Study.
    Mov Disord. 2022 Apr 14. doi: 10.1002/mds.29026.
    PubMed     Abstract available


  367. RAMIREZ J, Berberian SA, Breen DP, Gao F, et al
    Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients.
    Mov Disord. 2022 Apr 11. doi: 10.1002/mds.29010.
    PubMed     Abstract available


  368. QUATTRONE A, Bianco MG, Antonini A, Vaillancourt DE, et al
    Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
    Mov Disord. 2022 Apr 11. doi: 10.1002/mds.28992.
    PubMed     Abstract available


  369. UYAR M, Lezius S, Buhmann C, Potter-Nerger M, et al
    Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study).
    Mov Disord. 2022 Apr 6. doi: 10.1002/mds.29009.
    PubMed     Abstract available


  370. BARBA L, Paolini Paoletti F, Bellomo G, Gaetani L, et al
    Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers.
    Mov Disord. 2022;37:669-683.
    PubMed     Abstract available


  371. THIJSSEN E, den Heijer J, Puibert D, Moss L, et al
    A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.
    Mov Disord. 2022;37:790-798.
    PubMed     Abstract available


  372. GRIJALVA RM, Pham NTT, Huang Q, Martin PR, et al
    Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.
    Mov Disord. 2022;37:702-712.
    PubMed     Abstract available


    March 2022
  373. CHOUGAR L, Arsovic E, Gaurav R, Biondetti E, et al
    Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Mov Disord. 2022 Mar 29. doi: 10.1002/mds.28988.
    PubMed     Abstract available


  374. LE HERON C, MacAskill MR, Myall DJ
    Reply to: "An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis".
    Mov Disord. 2022 Mar 28. doi: 10.1002/mds.28989.
    PubMed    


  375. XU Y, Feeney MP, Surface M, Novak D, et al
    Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study.
    Mov Disord. 2022 Mar 26. doi: 10.1002/mds.28990.
    PubMed     Abstract available


  376. SIGURDSSON HP, Yarnall AJ, Galna B, Lord S, et al
    Gait-Related Metabolic Covariance Networks at Rest in Parkinson's Disease.
    Mov Disord. 2022 Mar 14. doi: 10.1002/mds.28977.
    PubMed     Abstract available


  377. NAKANO Y, Hirano S, Kojima K, Li H, et al
    Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders.
    Mov Disord. 2022 Mar 14. doi: 10.1002/mds.28981.
    PubMed     Abstract available


  378. LUAN M, Sun Y, Chen J, Jiang Y, et al
    Diagnostic Value of Salivary Real-Time Quaking-Induced Conversion in Parkinson's Disease and Multiple System Atrophy.
    Mov Disord. 2022 Mar 12. doi: 10.1002/mds.28976.
    PubMed     Abstract available


  379. MURTOMAKI K, Mertsalmi T, Jaakkola E, Makinen E, et al
    Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease.
    Mov Disord. 2022 Mar 11. doi: 10.1002/mds.28986.
    PubMed     Abstract available


  380. STRANIERO L, Rimoldi V, Monfrini E, Bonvegna S, et al
    Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk.
    Mov Disord. 2022 Mar 9. doi: 10.1002/mds.28987.
    PubMed     Abstract available


  381. KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
    Erratum to "Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Approach".
    Mov Disord. 2022 Mar 4. doi: 10.1002/mds.28974.
    PubMed    


  382. PRANGE S, Metereau E, Maillet A, Klinger H, et al
    Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease.
    Mov Disord. 2022 Mar 3. doi: 10.1002/mds.28971.
    PubMed     Abstract available


  383. OLSZEWSKA DA, Lang AE
    The Role of Insular Cortex in Gut-Inflammation Memory: What Does It Mean for Parkinson's Disease?
    Mov Disord. 2022 Mar 1. doi: 10.1002/mds.28975.
    PubMed    


  384. LIN CH, Lin HY, Ho EP, Ke YC, et al
    Reply to: Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF-alpha Pathway.
    Mov Disord. 2022;37:665-666.
    PubMed    


  385. SAMBIN S, Menon PJ, Ihle J, Mariani LL, et al
    Down-Regulation of Dopamine Transporter in Early Premotor Phases.
    Mov Disord. 2022;37:663-664.
    PubMed    


  386. LINARD M, Ravier A, Mougue L, Grgurina I, et al
    Infectious Agents as Potential Drivers of alpha-Synucleinopathies.
    Mov Disord. 2022;37:464-477.
    PubMed     Abstract available


  387. ROEDIGER J, Dembek TA, Wenzel G, Butenko K, et al
    StimFit-A Data-Driven Algorithm for Automated Deep Brain Stimulation Programming.
    Mov Disord. 2022;37:574-584.
    PubMed     Abstract available


  388. JANZEN A, Kogan RV, Meles SK, Sittig E, et al
    Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern.
    Mov Disord. 2022;37:624-629.
    PubMed     Abstract available


    February 2022
  389. RAO SC, Sanyaolu AO
    Breaking Barriers: Modeling the Blood-Brain Barrier in Parkinson's Disease Using a Human-Brain-Chip.
    Mov Disord. 2022 Feb 28. doi: 10.1002/mds.28968.
    PubMed    


  390. RASCOL O, Medori R, Baayen C, Such P, et al
    A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.
    Mov Disord. 2022 Feb 26. doi: 10.1002/mds.28970.
    PubMed     Abstract available


  391. KHALIL H, Aldaajani ZF, Aldughmi M, Al-Sharman A, et al
    Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Mov Disord. 2022 Feb 26. doi: 10.1002/mds.28905.
    PubMed     Abstract available


  392. CORNEJO-OLIVAS M, Wu L, Noyce A
    Disruption of Mitochondrial Complex I Induces Progressive Parkinsonism.
    Mov Disord. 2022 Feb 22. doi: 10.1002/mds.28961.
    PubMed    


  393. XING Y, Sapuan AH, Martin-Bastida A, Naidu S, et al
    Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis.
    Mov Disord. 2022 Feb 15. doi: 10.1002/mds.28934.
    PubMed     Abstract available


  394. LIZARRAGA KJ, Gnanamanogaran B, Al-Ozzi TM, Cohn M, et al
    Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2022 Feb 13. doi: 10.1002/mds.28953.
    PubMed     Abstract available


  395. MAGRINELLI F, Rajapaksha I, Kobylecki C, Latorre A, et al
    Reply to: Juvenile PLA2G6-parkinsonism due to Indian 'Asian' p.R741Q mutation, and response to STN DBS.
    Mov Disord. 2022 Feb 13. doi: 10.1002/mds.28955.
    PubMed    


  396. AYTON S, Hall S, Janelidze S, Kalinowski P, et al
    The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.
    Mov Disord. 2022 Feb 8. doi: 10.1002/mds.28958.
    PubMed     Abstract available


  397. PRASUHN J, Gottlich M, Grosser SS, Reuther K, et al
    In Vivo Brain Sodium Disequilibrium in ATP1A3-Related Rapid-Onset Dystonia-Parkinsonism.
    Mov Disord. 2022 Feb 7. doi: 10.1002/mds.28954.
    PubMed    


  398. MADELUNG CF, Meder D, Fuglsang SA, Marques MM, et al
    Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease.
    Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28945.
    PubMed     Abstract available


  399. RAVAT P, Shinde S, Shinde SR, Bangar S, et al
    Juvenile PLA2G6-Parkinsonism Due to Indian 'Asian' p.R741Q Mutation, and Response to STN DBS.
    Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28950.
    PubMed    


  400. SZWEDO AA, Dalen I, Pedersen KF, Camacho M, et al
    GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.
    Mov Disord. 2022 Feb 2. doi: 10.1002/mds.28932.
    PubMed     Abstract available


  401. ORTEGA RA, Bodamer O, Peake RWA, Raymond D, et al
    Assessment of Glucocerebrosidase Enzyme Activity in Parkinson Disease Using Multiple Approaches.
    Mov Disord. 2022 Feb 1. doi: 10.1002/mds.28951.
    PubMed    


  402. AAMODT WW, Chen-Plotkin AS
    Reply to: "Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)".
    Mov Disord. 2022;37:436-437.
    PubMed    


  403. TODT I, Al-Fatly B, Granert O, Kuhn AA, et al
    The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life.
    Mov Disord. 2022;37:291-301.
    PubMed     Abstract available


  404. D'CRUZ N, Seuthe J, De Somer C, Hulzinga F, et al
    Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait.
    Mov Disord. 2022;37:269-278.
    PubMed     Abstract available


  405. ZIRRA A, Huxford B
    CD4(+) T Cells Contribute to Neurodegeneration in Lewy Body Dementia.
    Mov Disord. 2022;37:268.
    PubMed    


    January 2022
  406. DERKINDEREN P, de Guilhem de Lataillade A, Neunlist M, Rolli-Derkinderen M, et al
    Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF-alpha Pathway.
    Mov Disord. 2022 Jan 31. doi: 10.1002/mds.28948.
    PubMed    


  407. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease.
    Mov Disord. 2022 Jan 29. doi: 10.1002/mds.28936.
    PubMed    


  408. LIU W, Yu Y
    Single-Trajectory Multiple Target for Parkinsonian Mobility and Cognition? An Inadvisable Idea.
    Mov Disord. 2022 Jan 28. doi: 10.1002/mds.28949.
    PubMed    


  409. GLEASON A, Tayebi N, Lopez G, Sidransky E, et al
    No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance.
    Mov Disord. 2022 Jan 24. doi: 10.1002/mds.28935.
    PubMed    


  410. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity.
    Mov Disord. 2022 Jan 22. doi: 10.1002/mds.28929.
    PubMed    


  411. GARRIDO A, Santamaria E, Fernandez-Irigoyen J, Soto M, et al
    Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
    Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28927.
    PubMed     Abstract available


  412. SUBRAMANIAN I, Mathur S, Oosterbaan A, Flanagan R, et al
    Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies.
    Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28921.
    PubMed     Abstract available


  413. MURATA H, Barnhill LM, Bronstein JM
    Air Pollution and the Risk of Parkinson's Disease: A Review.
    Mov Disord. 2022 Jan 19. doi: 10.1002/mds.28922.
    PubMed     Abstract available


  414. BUHMANN C, Lezius S, Potter-Nerger M, Gerloff C, et al
    Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD).
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28909.
    PubMed    


  415. COCHEN DE COCK V, Dotov D, Lacombe S, Picot MC, et al
    Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters.
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28894.
    PubMed     Abstract available


  416. VAN DER ZEE S, Kanel P, Gerritsen MJJ, Boertien JM, et al
    Altered Cholinergic Innervation in De Novo Parkinson's Disease with and without Cognitive Impairment.
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28913.
    PubMed     Abstract available


  417. MARTINEZ-VALBUENA I, Visanji NP, Olszewska DA, Sousa M, et al
    Combining Skin alpha-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease.
    Mov Disord. 2022 Jan 12. doi: 10.1002/mds.28912.
    PubMed    


  418. ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
    Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease.
    Mov Disord. 2022 Jan 9. doi: 10.1002/mds.28897.
    PubMed     Abstract available


  419. LEODORI G, De Bartolo MI, Guerra A, Fabbrini A, et al
    Motor Cortical Network Excitability in Parkinson's Disease.
    Mov Disord. 2022 Jan 9. doi: 10.1002/mds.28914.
    PubMed     Abstract available


  420. DOMENIGHETTI C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, et al
    Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study.
    Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28902.
    PubMed     Abstract available


  421. VANEGAS-ARROYAVE N, Chen DF, Lauro PM, Norato G, et al
    Where Do Parkinson's Disease Patients Look while Walking?
    Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28917.
    PubMed     Abstract available


  422. MERCHANT K, Sullivan J
    c-Abl Inhibitors as Disease-Modifying Therapies for Parkinson's Disease: Gaps and Opportunities.
    Mov Disord. 2022;37:3-5.
    PubMed    


  423. LA MORGIA C, Romagnoli M, Pizza F, Biscarini F, et al
    Chromatic Pupillometry in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2022;37:205-210.
    PubMed     Abstract available


    December 2021
  424. LEWIS SJG, Factor SA, Giladi N, Hallett M, et al
    Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28837.
    PubMed    


  425. BOHNEN NI, Costa RM, Dauer WT, Factor SA, et al
    Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28883.
    PubMed     Abstract available


  426. GUTTUSO T JR, Sirica D, Tosun D, Zivadinov R, et al
    Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28886.
    PubMed     Abstract available


  427. BOSHKOVSKI T, Cohen-Adad J, Misic B, Arnulf I, et al
    The Myelin-Weighted Connectome in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28891.
    PubMed     Abstract available


  428. DEVIGNES Q, Bordier C, Viard R, Defebvre L, et al
    Resting-State Functional Connectivity in Frontostriatal and Posterior Cortical Subtypes in Parkinson's Disease-Mild Cognitive Impairment.
    Mov Disord. 2021 Dec 17. doi: 10.1002/mds.28888.
    PubMed     Abstract available


  429. LIN CH, Lin HY, Ho EP, Ke YC, et al
    Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-alpha Pathway.
    Mov Disord. 2021 Dec 17. doi: 10.1002/mds.28890.
    PubMed     Abstract available


  430. ZOLFAGHARI S, Thomann AE, Lewandowski N, Trundell D, et al
    Self-Report versus Clinician Examination in Early Parkinson's Disease.
    Mov Disord. 2021 Dec 13. doi: 10.1002/mds.28884.
    PubMed     Abstract available


  431. BRUNO MK, Watanabe G, Ishikawa K, Chen JJ, et al
    Geographic Variation in Prescription Patterns of Parkinson's Disease Medications.
    Mov Disord. 2021 Dec 3. doi: 10.1002/mds.28880.
    PubMed    


  432. RODRIGUEZ-ROJAS R, Pineda-Pardo JA, Manez-Miro J, Sanchez-Turel A, et al
    Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease.
    Mov Disord. 2021 Dec 3. doi: 10.1002/mds.28862.
    PubMed     Abstract available


  433. MACIAS-GARCIA D, Perinan MT, Munoz-Delgado L, Jesus S, et al
    Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Mov Disord. 2021 Dec 2. doi: 10.1002/mds.28863.
    PubMed    


  434. GHIGLIERI V, Natale G
    Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation.
    Mov Disord. 2021;36:2979-2980.
    PubMed    


  435. GARCIA AM, Orozco-Arroyave JR
    Reply to: "Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease".
    Mov Disord. 2021;36:2982-2983.
    PubMed    


  436. RUSZ J, Tykalova T
    Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease?
    Mov Disord. 2021;36:2980-2982.
    PubMed    


  437. SUPPA A
    Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation.
    Mov Disord. 2021;36:2979.
    PubMed    


  438. YSSELSTEIN D, Young TJ, Nguyen M, Padmanabhan S, et al
    Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity.
    Mov Disord. 2021;36:2719-2730.
    PubMed     Abstract available


  439. VERHAGEN METMAN L, Slavin KV, Rosenow JM, Vitek JL, et al
    More Than Just the Level of Consciousness: Comparing Asleep and Awake Deep Brain Stimulation.
    Mov Disord. 2021;36:2763-2766.
    PubMed    


  440. FOIS AF, Mahant N, Vucic S, Fung VSC, et al
    Measuring Tremor-A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating.
    Mov Disord. 2021;36:2962-2963.
    PubMed    


    November 2021
  441. WERNER MH, Olanow CW
    Parkinson's Disease Modification through Abl Kinase Inhibition: An Opportunity.
    Mov Disord. 2021 Nov 23. doi: 10.1002/mds.28858.
    PubMed     Abstract available


  442. SCAMARCIA PG, Agosta F, Spinelli EG, Basaia S, et al
    Longitudinal White Matter Damage Evolution in Parkinson's Disease.
    Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28864.
    PubMed     Abstract available


  443. SASIKUMAR S, Cohn M, Harmsen IE, Loh A, et al
    Single-Trajectory Multiple-Target Deep Brain Stimulation for Parkinsonian Mobility and Cognition.
    Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28870.
    PubMed     Abstract available


  444. CHEN C, Mossman E, Malko P, McDonald D, et al
    Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson's Disease.
    Mov Disord. 2021 Nov 15. doi: 10.1002/mds.28849.
    PubMed     Abstract available


  445. COSENTINO C, Torres L, Velez M, Nunez Y, et al
    SARS-CoV-2 Vaccines and Motor Symptoms in Parkinson's Disease.
    Mov Disord. 2021 Nov 14. doi: 10.1002/mds.28851.
    PubMed    


  446. VOGEL A, Claus I, Ahring S, Gruber D, et al
    Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease.
    Mov Disord. 2021 Nov 13. doi: 10.1002/mds.28854.
    PubMed     Abstract available


  447. LANE EL, Harrison DJ, Ramos-Varas E, Hills R, et al
    Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.
    Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28856.
    PubMed     Abstract available


  448. SURMEIER DJ, Nguyen JT, Lancki N, Venuto CS, et al
    Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
    Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28850.
    PubMed     Abstract available


  449. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
    Mov Disord. 2021 Nov 6. doi: 10.1002/mds.28846.
    PubMed     Abstract available


  450. ARPIN DJ, Mitchell T, Archer DB, Burciu RG, et al
    Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
    Mov Disord. 2021 Nov 1. doi: 10.1002/mds.28838.
    PubMed     Abstract available


  451. LESCHZINER AE, Reck-Peterson SL
    Structural Biology of LRRK2 and its Interaction with Microtubules.
    Mov Disord. 2021;36:2494-2504.
    PubMed     Abstract available


  452. MANOR B, Dagan M, Herman T, Gouskova NA, et al
    Multitarget Transcranial Electrical Stimulation for Freezing of Gait: A Randomized Controlled Trial.
    Mov Disord. 2021;36:2693-2698.
    PubMed     Abstract available


  453. LERCHE S, Sjodin S, Brinkmalm A, Blennow K, et al
    CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB.
    Mov Disord. 2021;36:2595-2604.
    PubMed     Abstract available


  454. BORDERS JC, Sevitz JS, Curtis JA, Vanegas-Arroyave N, et al
    Sensorimotor Cough Dysfunction Is Prevalent and Pervasive in Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:2624-2633.
    PubMed     Abstract available


    October 2021
  455. CORVOL JC, Azulay JP, Bosse B, Dauvilliers Y, et al
    THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
    Mov Disord. 2021 Oct 28. doi: 10.1002/mds.28840.
    PubMed     Abstract available


  456. CHARISIS S, Ntanasi E, Stamelou M, Xiromerisiou G, et al
    Plasma Glutathione and Prodromal Parkinson's Disease Probability.
    Mov Disord. 2021 Oct 25. doi: 10.1002/mds.28826.
    PubMed     Abstract available


  457. VAN RENSBURG ZJ, Abrahams S, Chetty D, Step K, et al
    The South African Parkinson's Disease Study Collection.
    Mov Disord. 2021 Oct 22. doi: 10.1002/mds.28828.
    PubMed     Abstract available


  458. SAMBIN S, Lavisse S, Decaix C, Pyatigorskaya N, et al
    Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.
    Mov Disord. 2021 Oct 20. doi: 10.1002/mds.28833.
    PubMed    


  459. KLARENDIC M, Kirbis M, Mojsovska E, Kavcic M, et al
    Bee Venom Does Not Reduce the Risk for Parkinson's Disease: Epidemiological Study among Beekeepers.
    Mov Disord. 2021 Oct 16. doi: 10.1002/mds.28820.
    PubMed     Abstract available


  460. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Lower Circulating Lymphocyte Count Predicts ApoE epsilon4-Related Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28799.
    PubMed    


  461. HUXFORD B, Haque T, Joseph AB, Simonet C, et al
    Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity.
    Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28829.
    PubMed    


  462. JARAZO J, Barmpa K, Modamio J, Saraiva C, et al
    Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-beta-Cyclodextrin Treatment.
    Mov Disord. 2021 Oct 12. doi: 10.1002/mds.28810.
    PubMed     Abstract available


  463. SCHIRINZI T, Maftei D, Ralli M, Greco A, et al
    Serum Substance P Is Increased in Parkinson's Disease and Correlates with Motor Impairment.
    Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28824.
    PubMed    


  464. MAGRINELLI F, Mehta S, Di Lazzaro G, Latorre A, et al
    Dissecting the Phenotype and Genotype of PLA2G6-Related Parkinsonism.
    Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28807.
    PubMed     Abstract available


  465. PU JL, Jin CY, Wang ZX, Fang Y, et al
    Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28805.
    PubMed     Abstract available


  466. PIHLSTROM L, Fan CC, Frei O, Tan M, et al
    Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score.
    Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28808.
    PubMed     Abstract available


  467. JUCAITE A, Cselenyi Z, Kreisl WC, Rabiner EA, et al
    Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [(11) C]PBR28 and Machine Learning Analysis.
    Mov Disord. 2021 Oct 5. doi: 10.1002/mds.28814.
    PubMed     Abstract available


  468. GULER S, Gul T, Guler S, Haerle MC, et al
    Early-Onset Parkinson's Disease: A Novel Deletion Comprising the DJ-1 and TNFRSF9 Genes.
    Mov Disord. 2021 Oct 3. doi: 10.1002/mds.28812.
    PubMed     Abstract available


  469. CAMINITI SP, Carli G, Avenali M, Blandini F, et al
    Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations.
    Mov Disord. 2021 Oct 1. doi: 10.1002/mds.28818.
    PubMed     Abstract available


  470. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Reply to: "Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population".
    Mov Disord. 2021;36:2453.
    PubMed    


  471. ONG TL, Dal S, Williams LJ, Morales-Briceno H, et al
    \Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021;36:2452.
    PubMed    


  472. GAN-OR Z, Wood NW
    Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?
    Mov Disord. 2021;36:2220-2222.
    PubMed    


  473. NAMBU A
    Distinct Roles of the Dorsal Versus Ventral Subthalamic Nucleus.
    Mov Disord. 2021;36:2223.
    PubMed    


  474. ERRO R, Mencacci NE, Bhatia KP
    The Emerging Role of Phosphodiesterases in Movement Disorders.
    Mov Disord. 2021;36:2225-2243.
    PubMed     Abstract available


  475. CAMACHO M, Greenland JC, Williams-Gray CH
    The Gastrointestinal Dysfunction Scale for Parkinson's Disease.
    Mov Disord. 2021;36:2358-2366.
    PubMed     Abstract available


    September 2021
  476. REYES-PEREZ P, Bandres-Ciga S
    Identifying Genetic Markers Associated with the Progression of Cognitive Decline in Parkinson's Disease: A Call Out for Replication.
    Mov Disord. 2021 Sep 30. doi: 10.1002/mds.28798.
    PubMed    


  477. MILANOWSKI LM, Oshinaike O, Walton RL, Soto-Beasley AI, et al
    Screening of GBA Mutations in Nigerian Patients with Parkinson's Disease.
    Mov Disord. 2021 Sep 29. doi: 10.1002/mds.28803.
    PubMed    


  478. EVIDENTE VGH, Evidente DH, Ortega SC, Levine TD, et al
    X-Linked Dystonia-Parkinsonism ("Lubag") May Present with Peripheral Synucleinopathy.
    Mov Disord. 2021 Sep 28. doi: 10.1002/mds.28801.
    PubMed     Abstract available


  479. REN Y, Jiang H, Pu J, Li L, et al
    Molecular Features of Parkinson's Disease in Patient-Derived Midbrain Dopaminergic Neurons.
    Mov Disord. 2021 Sep 26. doi: 10.1002/mds.28786.
    PubMed     Abstract available


  480. BUCHANAN SM, Richards M, Schott JM, Schrag A, et al
    Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations.
    Mov Disord. 2021 Sep 25. doi: 10.1002/mds.28777.
    PubMed     Abstract available


  481. MAASS F, Michalke B, Willkommen D, Canaslan S, et al
    Cerebrospinal Fluid Iron-Ferritin Ratio as a Potential Progression Marker for Parkinson's Disease.
    Mov Disord. 2021 Sep 23. doi: 10.1002/mds.28790.
    PubMed     Abstract available


  482. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
    Mov Disord. 2021 Sep 22. doi: 10.1002/mds.28792.
    PubMed     Abstract available


  483. LAKE J, Reed X, Langston RG, Nalls MA, et al
    Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
    Mov Disord. 2021 Sep 20. doi: 10.1002/mds.28787.
    PubMed     Abstract available


  484. RENNER H, Scholer HR, Bruder JM
    Combining Automated Organoid Workflows With Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28775.
    PubMed     Abstract available


  485. POEWE W, Stocchi F, Arkadir D, Ebersbach G, et al
    Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28758.
    PubMed     Abstract available


  486. MAILLET A, Metereau E, Tremblay L, Favre E, et al
    Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28722.
    PubMed     Abstract available


  487. AAMODT WW, Waligorska T, Shen J, Tropea TF, et al
    Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
    Mov Disord. 2021 Sep 4. doi: 10.1002/mds.28779.
    PubMed     Abstract available


  488. LIN ZH, Zhang BR
    Striking While the Iron is Hot: The Role of Prosaposin (PSAP) in Parkinson's Disease.
    Mov Disord. 2021 Sep 3. doi: 10.1002/mds.28781.
    PubMed    


  489. ELSAYED I, Foote IF
    Improving Diversity in Parkinson's Disease Genetics: Findings from the First-Ever Genome-Wide Association Study in Latinos.
    Mov Disord. 2021 Sep 2. doi: 10.1002/mds.28782.
    PubMed    


  490. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Reply to: "Is Conscientiousness Related to the Risk of Parkinson's Disease?"
    Mov Disord. 2021;36:2216.
    PubMed    


  491. LUCA A, Nicoletti A, Zappia M
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021;36:2215.
    PubMed    


  492. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy".
    Mov Disord. 2021;36:2208-2209.
    PubMed    


  493. LIU H, Koros C, Stefanis L, Gasser T, et al
    Reply to: "alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism".
    Mov Disord. 2021;36:2212-2213.
    PubMed    


  494. RAU A, Jost WH, von der Warth R, Urbach H, et al
    Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:2207-2208.
    PubMed    


  495. TAN S, Baggio D, Shortt J, Ko B, et al
    Cardiovascular Safety of Nilotinib in Parkinson's Disease.
    Mov Disord. 2021;36:2217.
    PubMed    


  496. SOKRATOUS M, Breza M, Senkevich K, Gan-Or Z, et al
    alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism.
    Mov Disord. 2021;36:2209-2212.
    PubMed    


  497. ISHIMOTO T, Yamakado H
    Membranes and Organelle in Lewy Bodies: The Mastermind or the Bystander?
    Mov Disord. 2021;36:2026.
    PubMed    


  498. MAJBOUR NK, Abdi IY, Dakna M, Wicke T, et al
    Cerebrospinal alpha-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Mov Disord. 2021;36:2048-2056.
    PubMed     Abstract available


  499. ANDERSEN KB, Hansen AK, Damholdt MF, Horsager J, et al
    Reduced Synaptic Density in Patients with Lewy Body Dementia: An [(11) C]UCB-J PET Imaging Study.
    Mov Disord. 2021;36:2057-2065.
    PubMed     Abstract available


    August 2021
  500. LIU Y, Lawton MA, Lo C, Bowring F, et al
    Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study.
    Mov Disord. 2021 Aug 26. doi: 10.1002/mds.28763.
    PubMed     Abstract available


  501. KAINAGA M, Shirota Y, Kodama S, Toda T, et al
    Effects of the Coronavirus Disease 2019 Pandemic on Motor Symptoms in Parkinson's Disease: An Observational Study.
    Mov Disord. 2021 Aug 25. doi: 10.1002/mds.28766.
    PubMed    


  502. ONOFRJ M, Di Iorio A, Carrarini C, Russo M, et al
    Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease.
    Mov Disord. 2021 Aug 24. doi: 10.1002/mds.28745.
    PubMed     Abstract available


  503. KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
    Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach.
    Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28760.
    PubMed     Abstract available


  504. CAMPESE N, Goebel G, Leys F, Ndayisaba JP, et al
    Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?
    Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28768.
    PubMed    


  505. O'SHEA SA, Hickman RA, Cortes E, Vonsattel JP, et al
    Neuropathological Findings in a Case of Parkinsonism and Developmental Delay Associated with a Monoallelic Variant in PLXNA1.
    Mov Disord. 2021 Aug 20. doi: 10.1002/mds.28756.
    PubMed     Abstract available


  506. CIRNARU MD, Creus-Muncunill J, Nelson S, Lewis T, et al
    Striatal Cholinergic Dysregulation after Neonatal Decrease in X-Linked Dystonia Parkinsonism-Related TAF1 Isoforms.
    Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28750.
    PubMed     Abstract available


  507. SIA MW, Foo JN, Saffari SE, Wong AS, et al
    Polygenic Risk Scores in a Prospective Parkinson's Disease Cohort.
    Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28761.
    PubMed     Abstract available


  508. QI S, Yin P, Wang L, Qu M, et al
    Prevalence of Parkinson's Disease: A Community-Based Study in China.
    Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28762.
    PubMed     Abstract available


  509. GARCIA AM, Arias-Vergara T, C Vasquez-Correa J, Noth E, et al
    Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach.
    Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28751.
    PubMed     Abstract available


  510. LE HERON C, MacAskill M, Mason D, Dalrymple-Alford J, et al
    A Multi-Step Model of Parkinson's Disease Pathogenesis.
    Mov Disord. 2021 Aug 10. doi: 10.1002/mds.28719.
    PubMed     Abstract available


  511. ERRO R, Buonomo AR, Barone P, Pellecchia MT, et al
    Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson Disease.
    Mov Disord. 2021 Aug 9. doi: 10.1002/mds.28772.
    PubMed    


  512. OLANOW CW, Poewe W, Rascol O, Stocchi F, et al
    On-Demand Therapy for OFF Episodes in Parkinson's Disease.
    Mov Disord. 2021 Aug 7. doi: 10.1002/mds.28726.
    PubMed     Abstract available


  513. SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
    Risk Disclosure in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28723.
    PubMed     Abstract available


  514. OKUNOYE O, Horsfall L, Marston L, Walters K, et al
    Mortality of People with Parkinson's Disease in a Large UK-Based Cohort Study: Time Trends and Relationship to Disease Duration.
    Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28727.
    PubMed     Abstract available


  515. MARKAKI I, Ntetsika T, Svenningsson P
    Reply to: "HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study".
    Mov Disord. 2021;36:1993.
    PubMed    


  516. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Reply to: Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
    Mov Disord. 2021;36:1994-1995.
    PubMed    


  517. TORRES L, Velez M, Suarez R, Nunez Y, et al
    Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
    Mov Disord. 2021;36:1994.
    PubMed    


  518. ZITTEL S, Uyar M, Lezius S, Gerloff C, et al
    HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study.
    Mov Disord. 2021;36:1991-1992.
    PubMed    


  519. ZECH M, Jech R, Boesch S, Skorvanek M, et al
    Scoring Algorithm-Based Genomic Testing in Dystonia: A Prospective Validation Study.
    Mov Disord. 2021;36:1959-1964.
    PubMed     Abstract available


  520. KOSS DJ, Campesan S, Giorgini F, Outeiro TF, et al
    Dysfunction of RAB39B-Mediated Vesicular Trafficking in Lewy Body Diseases.
    Mov Disord. 2021;36:1744-1758.
    PubMed     Abstract available


  521. FASANO A, Gurevich T, Jech R, Kovacs N, et al
    Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
    Mov Disord. 2021;36:1853-1862.
    PubMed     Abstract available


  522. KIM R, Lee JY, Kim YK, Kim H, et al
    Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder-Related Metabolic Pattern Expression.
    Mov Disord. 2021;36:1889-1898.
    PubMed     Abstract available


    July 2021
  523. REN X, Lin J, Stebbins GT, Goetz CG, et al
    Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change.
    Mov Disord. 2021 Jul 30. doi: 10.1002/mds.28730.
    PubMed     Abstract available


  524. LAANSMA MA, Bright JK, Al-Bachari S, Anderson TJ, et al
    International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease.
    Mov Disord. 2021 Jul 20. doi: 10.1002/mds.28706.
    PubMed     Abstract available


  525. SARASSO E, Agosta F, Piramide N, Gardoni A, et al
    Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study.
    Mov Disord. 2021 Jul 19. doi: 10.1002/mds.28717.
    PubMed     Abstract available


  526. GROS P, Wang X, Guan J, Lang AE, et al
    Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease.
    Mov Disord. 2021 Jul 9. doi: 10.1002/mds.28712.
    PubMed     Abstract available


  527. CONCHA-MARAMBIO L, Farris CM, Holguin B, Ma Y, et al
    Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28715.
    PubMed    


  528. FREIRE-ALVAREZ E, Kurca E, Lopez Manzanares L, Pekkonen E, et al
    Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28703.
    PubMed     Abstract available


  529. MULLER-NEDEBOCK AC, Komolafe MA, Fawale MB, Carr JA, et al
    Copy Number Variation in Parkinson's Disease: An Update from Sub-Saharan Africa.
    Mov Disord. 2021 Jul 6. doi: 10.1002/mds.28710.
    PubMed    


  530. SCHILLING M, Lill CM
    MicroRNAs as Molecular Biomarkers for Parkinson's Disease Progression.
    Mov Disord. 2021 Jul 5. doi: 10.1002/mds.28700.
    PubMed    


  531. CHOONG CJ, Kimura Y, Mochizuki H
    Disturbed Mitochondria-Lysosome Crosstalk in GBA1-Associated Parkinson's Disease.
    Mov Disord. 2021 Jul 1. doi: 10.1002/mds.28693.
    PubMed    


  532. RASCOL O, Cochen de Cock V, Pavy-Le Traon A, Foubert-Samier A, et al
    Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.
    Mov Disord. 2021;36:1704-1711.
    PubMed     Abstract available


  533. SHILL HA, Zhang N, Driver-Dunckley E, Mehta S, et al
    Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:1700-1704.
    PubMed     Abstract available


  534. PERKINS JE, Janzen A, Bernhard FP, Wilhelm K, et al
    Saccade, Pupil, and Blink Responses in Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2021;36:1720-1726.
    PubMed     Abstract available


  535. DE ALMEIDA CMO, Brito MMC, Bosaipo NB, Pimentel AV, et al
    Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2021;36:1711-1715.
    PubMed     Abstract available


  536. WITTKE C, Petkovic S, Dobricic V, Schaake S, et al
    Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
    Mov Disord. 2021;36:1499-1510.
    PubMed     Abstract available


    June 2021
  537. VIDENOVIC A, Amara AW, Comella C, Schweitzer PK, et al
    Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
    Mov Disord. 2021 Jun 30. doi: 10.1002/mds.28702.
    PubMed     Abstract available


  538. PATEL SG, Buchanan CM, Mulroy E, Simpson M, et al
    Potential PINK1 Founder Effect in Polynesia Causing Early-Onset Parkinson's Disease.
    Mov Disord. 2021 Jun 22. doi: 10.1002/mds.28665.
    PubMed    


  539. FIORENZATO E, Antonini A, Bisiacchi P, Weis L, et al
    Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Jun 14. doi: 10.1002/mds.28682.
    PubMed     Abstract available


  540. NIGAM M, Ayadi I, Noiray C, Branquino-Bras AC, et al
    Sweet or Bland Dreams? Taste Loss in Isolated REM-Sleep Behavior Disorder and Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28692.
    PubMed     Abstract available


  541. GELPI E, Haberler C, Micko A, Polt A, et al
    Focal Subthalamic Atrophy After Long-Term Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28653.
    PubMed    


  542. MAITI B, Rawson KS, Tanenbaum AB, Koller JM, et al
    Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease.
    Mov Disord. 2021 Jun 10. doi: 10.1002/mds.28684.
    PubMed     Abstract available


  543. MUNOZ-DELGADO L, Macias-Garcia D, Jesus S, Martin-Rodriguez JF, et al
    Peripheral Immune Profile and Neutrophil-to-Lymphocyte Ratio in Parkinson's Disease.
    Mov Disord. 2021 Jun 8. doi: 10.1002/mds.28685.
    PubMed     Abstract available


  544. SEGER AD, Farrher E, Doppler CEJ, Gogishvili A, et al
    Putaminal y-Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease.
    Mov Disord. 2021 Jun 7. doi: 10.1002/mds.28674.
    PubMed     Abstract available


  545. HAMID E, Ayele BA, Massi DG, Ben Sassi S, et al
    Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent-Wide Survey.
    Mov Disord. 2021 Jun 3. doi: 10.1002/mds.28669.
    PubMed     Abstract available


  546. ISONAKA R, Goldstein DS, Zhu W, Yoon E, et al
    alpha-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease.
    Mov Disord. 2021 Jun 2. doi: 10.1002/mds.28667.
    PubMed     Abstract available


  547. MATHUR S
    Counting What Counts: How to Reach Outcomes That Truly Matter to Parkinson's Patients.
    Mov Disord. 2021;36:1290-1292.
    PubMed    


    May 2021
  548. CARVALHO V, Ferreira JJ, Correia Guedes L
    Tremor and Parkinsonism in Chromosomopathies - A Systematic Review.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28663.
    PubMed     Abstract available


  549. CONEYS R, Storm CS, Kia DA, Almramhi M, et al
    Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28662.
    PubMed     Abstract available


  550. FEARON C, Mikulis DJ, Lang AE
    Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28656.
    PubMed    


  551. BOUALI-BENAZZOUZ R, Benazzouz A
    Covid-19 Infection and Parkinsonism: Is There a Link?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28680.
    PubMed     Abstract available


  552. ORSO B, Arnaldi D, Girtler N, Brugnolo A, et al
    Dopaminergic and Serotonergic Degeneration and Cortical [(18) F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28654.
    PubMed     Abstract available


  553. DEAN DN, Lee JC
    Linking Parkinson's Disease and Melanoma: Interplay Between alpha-Synuclein and Pmel17 Amyloid Formation.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28655.
    PubMed     Abstract available


  554. SCHWEDHELM E, Englisch C, Niemann L, Lezius S, et al
    Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD).
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28652.
    PubMed     Abstract available


  555. TOFFOLI M, Higgins A, Lee C, Koletsi S, et al
    Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease.
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28616.
    PubMed     Abstract available


  556. STUENDL A, Kraus T, Chatterjee M, Zapke B, et al
    alpha-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28639.
    PubMed     Abstract available


  557. O'SULLIVAN JM, den Heijer JM, Groeneveld GJ, Cooper AA, et al
    Intronic Haplotypes in GBA Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28620.
    PubMed    


  558. HAN F, Brown GL, Zhu Y, Belkin-Rosen AE, et al
    Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline.
    Mov Disord. 2021 May 17. doi: 10.1002/mds.28643.
    PubMed     Abstract available


  559. MORLEY D, Dummett S, Kelly L, Jenkinson C, et al
    Development of an Exercise-Specific Parkinson's Disease Questionnaire: The PDQ-Exercise.
    Mov Disord. 2021 May 15. doi: 10.1002/mds.28644.
    PubMed     Abstract available


  560. MARRAS C, Mills KA, Eberly S, Oakes D, et al
    Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients With Early Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28641.
    PubMed     Abstract available


  561. RICCIARDI L, Fischer P, Mostofi A, Tinkhauser G, et al
    Neurophysiological Correlates of Trait Impulsivity in Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28625.
    PubMed     Abstract available


  562. ESTIAR MA, Senkevich K, Yu E, Varghaei P, et al
    Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28640.
    PubMed     Abstract available


  563. COLLOBY SJ, Nathan PJ, Bakker G, Lawson RA, et al
    Spatial Covariance of Cholinergic Muscarinic M1 /M4 Receptors in Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28564.
    PubMed     Abstract available


  564. NAITO T, Satake W, Ogawa K, Suzuki K, et al
    Trans-Ethnic Fine-Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28583.
    PubMed     Abstract available


  565. BARBUTI PA, Barker RA, Brundin P, Przedborski S, et al
    Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease.
    Mov Disord. 2021 May 8. doi: 10.1002/mds.28628.
    PubMed     Abstract available


  566. IWAKI H, Leonard HL, Makarious MB, Bookman M, et al
    Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28549.
    PubMed     Abstract available


  567. DI LAZZARO G, Magrinelli F, Estevez-Fraga C, Valente EM, et al
    X-Linked Parkinsonism: Phenotypic and Genetic Heterogeneity.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28565.
    PubMed     Abstract available


  568. MCINTOSH E, Kent S, Gray A, Clarke CE, et al
    Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28623.
    PubMed     Abstract available


  569. MIRELMAN A, Ben Or Frank M, Melamed M, Granovsky L, et al
    Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28631.
    PubMed     Abstract available


  570. KAASINEN V, Vahlberg T, Stoessl AJ, Strafella AP, et al
    Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28632.
    PubMed     Abstract available


  571. KREMER T, Taylor KI, Siebourg-Polster J, Gerken T, et al
    Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28608.
    PubMed     Abstract available


  572. SCHERBAUM R, Kwon EH, Richter D, Bartig D, et al
    Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28586.
    PubMed     Abstract available


  573. MESTRE TA, Macklin EA, Ascherio A, Ferreira JJ, et al
    Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28630.
    PubMed     Abstract available


  574. SCOTT GD, Lim MM, Drake MG, Woltjer R, et al
    Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans.
    Mov Disord. 2021 May 3. doi: 10.1002/mds.28636.
    PubMed     Abstract available


  575. KIEBURTZ K, Olanow CW
    Reply to: "A New Approach to the Development of Disease-Modifying Therapies for PD".
    Mov Disord. 2021;36:1281-1282.
    PubMed    


  576. SIMON DK
    A New Approach to the Development of Disease-Modifying Therapies for PD.
    Mov Disord. 2021;36:1281.
    PubMed    


  577. LERCHE S, Schulte C, Wurster I, Machetanz G, et al
    The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PDGBA.
    Mov Disord. 2021;36:1216-1228.
    PubMed     Abstract available


    April 2021
  578. YILMAZ R, Suenkel U, Postuma RB, Heinzel S, et al
    Comparing the Two Prodromal Parkinson's Disease Research Criteria-Lessons for Future Studies.
    Mov Disord. 2021 Apr 30. doi: 10.1002/mds.28637.
    PubMed    


  579. SARANZA G, Villanueva EQ 3rd, Lang AE
    Preferences for Communication About End-of-Life Care in Atypical Parkinsonism.
    Mov Disord. 2021 Apr 28. doi: 10.1002/mds.28633.
    PubMed     Abstract available


  580. HUYNH B, Fu Y, Kirik D, Shine JM, et al
    Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease.
    Mov Disord. 2021 Apr 26. doi: 10.1002/mds.28615.
    PubMed     Abstract available


  581. TSUNEMI T, Oyama G, Saiki S, Hatano T, et al
    Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
    Mov Disord. 2021 Apr 25. doi: 10.1002/mds.28595.
    PubMed     Abstract available


  582. LETA V, Rodriguez-Violante M, Abundes A, Rukavina K, et al
    Parkinson's disease and Post-COVID-19 syndrome: The Parkinson's Long-COVID spectrum.
    Mov Disord. 2021 Apr 22. doi: 10.1002/mds.28622.
    PubMed    


  583. LI C, Ou R, Chen Y, Gu X, et al
    Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genome-Wide Association Study.
    Mov Disord. 2021 Apr 21. doi: 10.1002/mds.28621.
    PubMed     Abstract available


  584. CHEN Y, Wu W, Zhao S, Lv X, et al
    Increased Accumulation of alpha-Synuclein in Inflamed Appendices of Parkinson's Disease Patients.
    Mov Disord. 2021 Apr 20. doi: 10.1002/mds.28553.
    PubMed     Abstract available


  585. JOHNSON LA, Aman JE, Yu Y, Escobar Sanabria D, et al
    High-Frequency Oscillations in the Pallidum: A Pathophysiological Biomarker in Parkinson's Disease?
    Mov Disord. 2021 Apr 13. doi: 10.1002/mds.28566.
    PubMed     Abstract available


  586. SOARES C, Carneiro DR, Dias R, Ferreira D, et al
    Behind the mask: recognizing facial features of Parkinson's disease during the COVID-19 pandemic.
    Mov Disord. 2021 Apr 9. doi: 10.1002/mds.28619.
    PubMed    


  587. ZAHED H, Zuzuarregui JRP, Gilron R, Denison T, et al
    The Neurophysiology of Sleep in Parkinson's Disease.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28562.
    PubMed     Abstract available


  588. LIM SH, Ferdousi M, Kalteniece A, Mahfoud ZR, et al
    Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28602.
    PubMed     Abstract available


  589. JIANG C, Hopfner F, Berg D, Hu MT, et al
    Validation of alpha-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28591.
    PubMed     Abstract available


  590. KOOHI N, Bancroft MJ, Patel J, Castro P, et al
    Saccadic Bradykinesia in Parkinson's Disease: Preliminary Observations.
    Mov Disord. 2021 Apr 6. doi: 10.1002/mds.28609.
    PubMed    


  591. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28575.
    PubMed     Abstract available


  592. UEDA J, Uemura N, Sawamura M, Taguchi T, et al
    Perampanel Inhibits alpha-Synuclein Transmission in Parkinson's Disease Models.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28558.
    PubMed     Abstract available


  593. NIJHUIS FAP, Esselink R, de Bie RMA, Groenewoud H, et al
    Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
    Mov Disord. 2021 Apr 2. doi: 10.1002/mds.28599.
    PubMed     Abstract available


  594. HELMICH RC, Van den Berg KRE, Panyakaew P, Cho HJ, et al
    Cerebello-Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease.
    Mov Disord. 2021 Apr 1. doi: 10.1002/mds.28603.
    PubMed    


  595. GUTTLER C, Nikulin VV, van Riesen C
    Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
    Mov Disord. 2021;36:1045-1047.
    PubMed    


  596. SCHMIDT SL, Grill WM
    Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2021;36:1044-1045.
    PubMed    


  597. NEUMANN WJ, Rodriguez-Oroz MC
    Machine Learning Will Extend the Clinical Utility of Adaptive Deep Brain Stimulation.
    Mov Disord. 2021;36:796-799.
    PubMed    


  598. RUSZ J, Tykalova T, Ramig LO, Tripoliti E, et al
    Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders.
    Mov Disord. 2021;36:803-814.
    PubMed     Abstract available


  599. GEORGIEV D, Roskar S, Cus A, Wilkinson L, et al
    STN-DBS Increases Proactive but Not Retroactive Interference During Verbal Learning in PD.
    Mov Disord. 2021;36:1010-1015.
    PubMed     Abstract available


  600. OSHIMA S, Fushimi Y, Okada T, Nakajima S, et al
    Neuromelanin-Sensitive Magnetic Resonance Imaging Using DANTE Pulse.
    Mov Disord. 2021;36:874-882.
    PubMed     Abstract available


  601. BOOTH S, Ramadan A, Zhang D, Lu L, et al
    The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
    Mov Disord. 2021;36:938-947.
    PubMed     Abstract available


    March 2021
  602. VISANJI NP, Lang AE
    Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28590.
    PubMed    


  603. KLUGER BM, Dolhun R, Sumrall M, Hall K, et al
    Palliative Care and Parkinson's Disease: Time to Move Beyond Cancer.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28556.
    PubMed    


  604. SCHIESS M, Suescun J, Doursout MF, Adams C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease.
    Mov Disord. 2021 Mar 27. doi: 10.1002/mds.28582.
    PubMed     Abstract available


  605. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021 Mar 25. doi: 10.1002/mds.28594.
    PubMed     Abstract available


  606. GROVER S, Kumar-Sreelatha AA, Bobbili DR, May P, et al
    Replication of a Novel Parkinson's Locus in a European Ancestry Population.
    Mov Disord. 2021 Mar 24. doi: 10.1002/mds.28546.
    PubMed     Abstract available


  607. ABRAHAM DS, Pham Nguyen TP, Willis AW
    Claims-Based Frailty and Outcomes: Applying an Aging Measure to Older Adults with Parkinson's Disease.
    Mov Disord. 2021 Mar 23. doi: 10.1002/mds.28561.
    PubMed     Abstract available


  608. YAO CW, Saha-Chaudhuri P, Zolfaghari S, Pelletier A, et al
    Phenoconversion from Possible REM Sleep Behavior to Parkinsonism in the Population-Based CLSA.
    Mov Disord. 2021 Mar 22. doi: 10.1002/mds.28571.
    PubMed    


  609. SALARI M, Etemadifar M, Zali A, Medghalchi A, et al
    Seroprevalence of SARS-CoV-2 in Parkinson's Disease Patients: A Case-Control Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28580.
    PubMed    


  610. MARINI K, Seppi K, Tschiderer L, Kiechl S, et al
    Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28570.
    PubMed    


  611. CANONICO M, Pesce G, Bonaventure A, Le Noan-Laine M, et al
    Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy.
    Mov Disord. 2021 Mar 16. doi: 10.1002/mds.28563.
    PubMed     Abstract available


  612. DOBKIN RD, Mann SL, Weintraub D, Rodriguez KM, et al
    Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment.
    Mov Disord. 2021 Mar 12. doi: 10.1002/mds.28548.
    PubMed     Abstract available


  613. GAURAV R, Yahia-Cherif L, Pyatigorskaya N, Mangone G, et al
    Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Mov Disord. 2021 Mar 10. doi: 10.1002/mds.28531.
    PubMed     Abstract available


  614. CHOHAN H, Senkevich K, Patel RK, Bestwick JP, et al
    Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
    Mov Disord. 2021 Mar 8. doi: 10.1002/mds.28551.
    PubMed     Abstract available


  615. DUYSENS J, Nonnekes J
    Parkinson's Kinesia Paradoxa Is Not a Paradox.
    Mov Disord. 2021 Mar 3. doi: 10.1002/mds.28550.
    PubMed    


  616. CLAUS I, Muhle P, Czechowski J, Ahring S, et al
    Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease.
    Mov Disord. 2021 Mar 2. doi: 10.1002/mds.28552.
    PubMed     Abstract available


  617. FEARON C, Lang AE, Espay AJ
    The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes.
    Mov Disord. 2021;36:594-598.
    PubMed    


  618. BORGHAMMER P, Horsager J
    The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes.
    Mov Disord. 2021;36:785-786.
    PubMed    


  619. FEARON C, Lang AE, J Espay A
    Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes".
    Mov Disord. 2021;36:786-787.
    PubMed    


  620. SARTER M, Avila C, Kucinski A, Donovan E, et al
    Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements.
    Mov Disord. 2021;36:535-546.
    PubMed     Abstract available


  621. YOUNCE JR, Campbell MC, Hershey T, Tanenbaum AB, et al
    Resting-State Functional Connectivity Predicts STN DBS Clinical Response.
    Mov Disord. 2021;36:662-671.
    PubMed     Abstract available


  622. POLISSIDIS A, Koronaiou M, Kollia V, Koronaiou E, et al
    Psychosis-Like Behavior and Hyperdopaminergic Dysregulation in Human alpha-Synuclein BAC Transgenic Rats.
    Mov Disord. 2021;36:716-728.
    PubMed     Abstract available


  623. HANSS Z, Larsen SB, Antony P, Mencke P, et al
    Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
    Mov Disord. 2021;36:704-715.
    PubMed     Abstract available


    February 2021
  624. DE MICCO R, Agosta F, Basaia S, Siciliano M, et al
    Functional Connectomics and Disease Progression in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28541.
    PubMed     Abstract available


  625. BURTSCHER J, Syed MMK, Lashuel HA, Millet GP, et al
    Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28544.
    PubMed     Abstract available


  626. MARKAKI I, Ntetsika T, Sorjonen K, Svenningsson P, et al
    Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28545.
    PubMed     Abstract available


  627. CHAHINE LM, Zhu X, Ehrenkranz R, Chen H, et al
    Changes in Self-Reported Energy Levels in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28535.
    PubMed    


  628. KAKAR RS, Pastor JV, Moe OW, Ambrosio F, et al
    Peripheral Klotho and Parkinson's Disease.
    Mov Disord. 2021 Feb 25. doi: 10.1002/mds.28530.
    PubMed    


  629. MOONEN AJH, Mulders AEP, Defebvre L, Duits A, et al
    Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28533.
    PubMed     Abstract available


  630. AVENALI M, Cerri S, Ongari G, Ghezzi C, et al
    Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28496.
    PubMed     Abstract available


  631. LIU H, Koros C, Strohaker T, Schulte C, et al
    A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28534.
    PubMed     Abstract available


  632. SONG S, Luo Z, Li C, Huang X, et al
    Changes in Body Composition Before and After Parkinson's Disease Diagnosis.
    Mov Disord. 2021 Feb 22:e28536. doi: 10.1002/mds.28536.
    PubMed     Abstract available


  633. AEED F, Cermak N, Schiller J, Schiller Y, et al
    Intrinsic Disruption of the M1 Cortical Network in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2021 Feb 19. doi: 10.1002/mds.28538.
    PubMed     Abstract available


  634. KLEINER G, Fernandez HH, Chou KL, Fasano A, et al
    Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire.
    Mov Disord. 2021 Feb 15. doi: 10.1002/mds.28507.
    PubMed     Abstract available


  635. GALPER J, Balwani M, Fahn S, Waters C, et al
    Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers With and Without Parkinson Disease.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28525.
    PubMed     Abstract available


  636. BRIGHT JM, Carlisle HJ, Toda AMA, Murphy M, et al
    Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28490.
    PubMed     Abstract available


  637. PAZ RM, Tubert C, Stahl AM, Amarillo Y, et al
    Levodopa Causes Striatal Cholinergic Interneuron Burst-Pause Activity in Parkinsonian Mice.
    Mov Disord. 2021 Feb 6. doi: 10.1002/mds.28516.
    PubMed     Abstract available


  638. ANTAR T, Iwaki H, B Singleton A
    Reply to: 'Letter to the Editor on "Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities"'.
    Mov Disord. 2021;36:527-528.
    PubMed    


  639. OUTEIRO TF, Krisko A
    Reply to: "Parkinson's Disease and COVID-19: Do We Need to Be More Patient?"
    Mov Disord. 2021;36:278-279.
    PubMed    


  640. GONZALEZ-LATAPI P, Fearon C, Fasano A, Lang AE, et al
    Parkinson's Disease and COVID-19: Do We Need to Be More Patient?
    Mov Disord. 2021;36:277.
    PubMed    


  641. DE LA ROSA T, Amado Scerni D, Scorza FA
    Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities.
    Mov Disord. 2021;36:526.
    PubMed    


  642. HO GPH, Ramalingam N, Imberdis T, Wilkie EC, et al
    Upregulation of Cellular Palmitoylation Mitigates alpha-Synuclein Accumulation and Neurotoxicity.
    Mov Disord. 2021;36:348-359.
    PubMed     Abstract available


    January 2021
  643. MULLER-NEDEBOCK AC, van der Westhuizen FH, Koks S, Bardien S, et al
    Nuclear Genes Associated with Mitochondrial DNA Processes as Contributors to Parkinson's Disease Risk.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28475.
    PubMed     Abstract available


  644. JEONG SH, Lee HS, Jung JH, Baik K, et al
    White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28510.
    PubMed     Abstract available



  645. GP2: The Global Parkinson's Genetics Program.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28494.
    PubMed    


  646. KIM JJ, Makarious MB, Bandres-Ciga S, Gibbs JR, et al
    The Parkinson's Disease DNA Variant Browser.
    Mov Disord. 2021 Jan 26. doi: 10.1002/mds.28488.
    PubMed     Abstract available


  647. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28462.
    PubMed     Abstract available


  648. DONAHUE EK, Murdos A, Jakowec MW, Sheikh-Bahaei N, et al
    Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28473.
    PubMed     Abstract available


  649. WELTON T, Tan EK
    Applying Artificial Intelligence to Multi-Omic Data: New Functional Variants in Parkinson's Disease.
    Mov Disord. 2021 Jan 17. doi: 10.1002/mds.28481.
    PubMed    


  650. MICHELI F, Vissani M, Pecchioli G, Terenzi F, et al
    Impulsivity Markers in Parkinsonian Subthalamic Single-Unit Activity.
    Mov Disord. 2021 Jan 16. doi: 10.1002/mds.28497.
    PubMed     Abstract available


  651. AVRAM CM, Brumbach BH, Hiller AL
    A Report of Tamoxifen and Parkinson's Disease in a US Population and a Review of the Literature.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28471.
    PubMed     Abstract available


  652. LIN CH, Chang CH, Tai CH, Cheng MF, et al
    A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28474.
    PubMed     Abstract available


  653. RAVANIDIS S, Bougea A, Karampatsi D, Papagiannakis N, et al
    Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 12. doi: 10.1002/mds.28467.
    PubMed     Abstract available


  654. HERZ DM, Meder D, Camilleri JA, Eickhoff SB, et al
    Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta-Analytic Modeling.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28468.
    PubMed     Abstract available


  655. VILA-VICOSA D, Clemente A, Pona-Ferreira F, Leitao M, et al
    Unsupervised walking activity assessment reveals COVID-19 impact on Parkinson's disease patients.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28514.
    PubMed    


  656. ZARKALI A, McColgan P, Leyland LA, Lees AJ, et al
    Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.
    Mov Disord. 2021 Jan 9. doi: 10.1002/mds.28477.
    PubMed     Abstract available


  657. KUUSIMAKI T, Al-Abdulrasul H, Kurki S, Hietala J, et al
    Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28484.
    PubMed     Abstract available


  658. CHEN L, Bedard P, Hallett M, Horovitz SG, et al
    Dynamics of Top-Down Control and Motor Networks in Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28461.
    PubMed     Abstract available


  659. SCHIRINZI T, Maftei D, Pieri M, Bernardini S, et al
    Increase of Prokineticin-2 in Serum of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28458.
    PubMed    


  660. METCALFE-ROACH A, Yu AC, Golz E, Cirstea M, et al
    MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28464.
    PubMed     Abstract available


  661. BAUMGARTNER AJ, Press DZ, Simon DK
    The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28483.
    PubMed    


  662. CHOE CU, Potter-Nerger M, Buhmann C, Blankenberg S, et al
    Reply to: "Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease".
    Mov Disord. 2021;36:273-274.
    PubMed    


  663. TRILCK-WINKLER M, Borsche M, Konig IR, Balck A, et al
    Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
    Mov Disord. 2021;36:271-273.
    PubMed    


  664. WITT K
    The Impact of the Basal Ganglia on Working Memory: Evidence from Parkinson's Disease.
    Mov Disord. 2021;36:13-15.
    PubMed    


  665. FULLER RLM, Sanchez-Ferro A, Goetz CG, Martinez-Martin P, et al
    In Support of Electronic Versions of Movement Disorder Society Rating Scales.
    Mov Disord. 2021;36:270-271.
    PubMed    


  666. TURNER TH, Dale ML
    Reply to: "In Support of Electronic Versions of Movement Disorder Society Rating Scales".
    Mov Disord. 2021;36:271.
    PubMed    


  667. SARANZA G, Lang AE
    Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
    Mov Disord. 2021;36:265-266.
    PubMed    


  668. KIEBURTZ K, Katz R, McGarry A, Olanow CW, et al
    A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
    Mov Disord. 2021;36:59-63.
    PubMed     Abstract available


  669. VIEIRA-YANO B, Martini DN, Horak FB, de Lima-Pardini A, et al
    The Adapted Resistance Training with Instability Randomized Controlled Trial for Gait Automaticity.
    Mov Disord. 2021;36:152-163.
    PubMed     Abstract available


    December 2020
  670. WILSON J, Yarnall AJ, Craig CE, Galna B, et al
    Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
    Mov Disord. 2020 Dec 31. doi: 10.1002/mds.28453.
    PubMed     Abstract available


  671. DUITS AA, Boots LMM, Mulders AEP, Moonen AJH, et al
    Covid Proof Self-Management Training for Caregivers of Patients with Parkinson's Disease.
    Mov Disord. 2020 Dec 27. doi: 10.1002/mds.28457.
    PubMed    


  672. FILIPPOU P, Outeiro TF
    Cancer and Parkinson's Disease: Common Targets, Emerging Hopes.
    Mov Disord. 2020 Dec 21. doi: 10.1002/mds.28425.
    PubMed     Abstract available


  673. NISSEN SK, Ferreira SA, Nielsen MC, Schulte C, et al
    Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.
    Mov Disord. 2020 Dec 17. doi: 10.1002/mds.28424.
    PubMed     Abstract available


  674. ZOON TJC, van Rooijen G, Balm GMFC, Bergfeld IO, et al
    Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2020 Dec 16. doi: 10.1002/mds.28390.
    PubMed     Abstract available


  675. SKRAHINA V, Gaber H, Vollstedt EJ, Forster TM, et al
    The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28416.
    PubMed     Abstract available


  676. KLINE EM, Houser MC, Herrick MK, Seibler P, et al
    Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28411.
    PubMed     Abstract available


  677. ELFIL M, Bahbah EI, Attia MM, Eldokmak M, et al
    Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease.
    Mov Disord. 2020 Dec 9. doi: 10.1002/mds.28412.
    PubMed     Abstract available


  678. MULLIN S, Stokholm MG, Hughes D, Mehta A, et al
    Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease.
    Mov Disord. 2020 Dec 5. doi: 10.1002/mds.28375.
    PubMed     Abstract available


  679. CAREY G, Gormezoglu M, de Jong JJA, Hofman PAM, et al
    Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2020 Dec 2. doi: 10.1002/mds.28404.
    PubMed     Abstract available


  680. OLSZEWSKA DA, Lang AE
    "Opening" New Insights Into LRRK2 Conformation and the Microtubule.
    Mov Disord. 2020;35:2162-2163.
    PubMed    


    November 2020
  681. MARTIN WRW, Miles M, Zhong Q, Hartlein J, et al
    Is Levodopa Response a Valid Indicator of Parkinson's Disease?
    Mov Disord. 2020 Nov 30. doi: 10.1002/mds.28406.
    PubMed     Abstract available


  682. GUTTLER C, Altschuler J, Tanev K, Bockmann S, et al
    Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2020 Nov 28. doi: 10.1002/mds.28403.
    PubMed     Abstract available


  683. PORTLEY MK, Scholz SW
    Hot Topic: Epigenetics in Parkinson's Disease: A New Frontier for Disease-Modifying Therapies.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28410.
    PubMed    


  684. SANTOS-GARCIA D, Pozojevic J, de Deus Fonticoba T, Kurtis M, et al
    First Case of Parkinsonian-Pyramidal Syndrome Associated with a TBK1 Mutation.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28405.
    PubMed    


  685. WALDTHALER J, Stock L, Sommerkorn J, Kruger-Zechlin C, et al
    Antisaccade Latency Is Sensitive to Longitudinal Change of Motor and Cognitive Symptoms in Parkinson's Disease.
    Mov Disord. 2020 Nov 25. doi: 10.1002/mds.28374.
    PubMed    


  686. AL-QASSABI A, Tsao TS, Racolta A, Kremer T, et al
    Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28399.
    PubMed     Abstract available


  687. JAAKKOLA E, Huovinen A, Kaasinen V, Joutsa J, et al
    No Change in Prevalence of Impulse Control Disorder Behaviors in Parkinson's Disease During the Last Decade.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28400.
    PubMed    


  688. GARCIA-SANZ P, M F G Aerts J, Moratalla R
    The Role of Cholesterol in alpha-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease.
    Mov Disord. 2020 Nov 21. doi: 10.1002/mds.28396.
    PubMed     Abstract available


  689. PAGAN FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, et al
    Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
    Mov Disord. 2020 Nov 20. doi: 10.1002/mds.28389.
    PubMed     Abstract available


  690. ERREA O, Rodriguez-Oroz MC
    Oligodendrocytes, a New Player in the Etiology of Parkinson's Disease.
    Mov Disord. 2020 Nov 18. doi: 10.1002/mds.28393.
    PubMed    


  691. OJUKWU DI, Andruska KM, Halpern CH
    Lessons From George Floyd: Racial Inequalities in the Treatment of Parkinson's Disease.
    Mov Disord. 2020 Nov 17. doi: 10.1002/mds.28388.
    PubMed    


  692. ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
    Adenosine A2A Receptor Occupancy by Long-Term Istradefylline Administration in Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28378.
    PubMed    


  693. OUTEIRO TF, Heutink P, Bezard E, Cenci AM, et al
    From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28387.
    PubMed     Abstract available


  694. VIGNATELLI L, Zenesini C, Belotti LMB, Baldin E, et al
    Risk of hospitalization and death for COVID-19 in people with Parkinson's disease or parkinsonism.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28408.
    PubMed     Abstract available


  695. MAETZLER W, Rochester L, Bhidayasiri R, Espay AJ, et al
    Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures.
    Mov Disord. 2020 Nov 15. doi: 10.1002/mds.28377.
    PubMed     Abstract available


  696. DEVOS D, Hirsch E, Wyse R
    Seven Solutions for Neuroprotection in Parkinson's Disease.
    Mov Disord. 2020 Nov 13. doi: 10.1002/mds.28379.
    PubMed     Abstract available


  697. DE MICCO R, Satolli S, Siciliano M, Di Nardo F, et al
    Connectivity Correlates of Anxiety Symptoms in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 10. doi: 10.1002/mds.28372.
    PubMed     Abstract available


  698. PICILLO M, Phokaewvarangkul O, Poon YY, McIntyre CC, et al
    Levodopa Versus Dopamine Agonist After Subthalamic Stimulation in Parkinson's Disease.
    Mov Disord. 2020 Nov 9. doi: 10.1002/mds.28382.
    PubMed     Abstract available


  699. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28364.
    PubMed     Abstract available


  700. SARIHAN EI, Perez-Palma E, Niestroj LM, Loesch D, et al
    Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28353.
    PubMed     Abstract available


  701. VAN DER ZEE S, Muller MLTM, Kanel P, van Laar T, et al
    Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28360.
    PubMed     Abstract available


  702. CHOUGAR L, Faouzi J, Pyatigorskaya N, Yahia-Cherif L, et al
    Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28348.
    PubMed     Abstract available


  703. DORSEY ER, Bloem BR, Okun MS
    A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders.
    Mov Disord. 2020;35:1897-1902.
    PubMed     Abstract available


  704. HERRINGTON TM, Schweitzer J, Henchcliffe C, Carter BS, et al
    Toward a Personalized Approach to Parkinson's Cell Therapy.
    Mov Disord. 2020;35:2119-2120.
    PubMed    


  705. SILVA-BATISTA C, M Corcos D, B Horak F, Ugrinowitsch C, et al
    Reply to: 'Letter to the Editor on "A Randomized Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait"'.
    Mov Disord. 2020;35:2123-2124.
    PubMed    


  706. KORDOWER JH, Okun MS, Jankovic J
    Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy".
    Mov Disord. 2020;35:2120-2121.
    PubMed    


  707. NONNEKES J, Gilat M, D'Cruz N, Dijkstra BW, et al
    Letter to the Editor on "A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait".
    Mov Disord. 2020;35:2122-2123.
    PubMed    


    October 2020
  708. TAN MMX, Lawton MA, Jabbari E, Reynolds RH, et al
    Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2020 Oct 28. doi: 10.1002/mds.28342.
    PubMed     Abstract available


  709. SUN YM, Yu HL, Zhou XY, Xiong WX, et al
    Disease Progression in Patients with Parkin-Related Parkinson's Disease in a Longitudinal Cohort.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28349.
    PubMed     Abstract available


  710. MENOZZI E, Macnaughtan J, Schapira AHV
    LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28347.
    PubMed    


  711. VAN DEN HEUVEL L, Evers L, Meinders M, Post B, et al
    Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28339.
    PubMed     Abstract available


  712. BEYLERGIL SB, Petersen M, Gupta P, Elkasaby M, et al
    Severity-Dependent Effects of Parkinson's Disease on Perception of Visual and Vestibular Heading.
    Mov Disord. 2020 Oct 26. doi: 10.1002/mds.28352.
    PubMed     Abstract available


  713. YE Z, Zhang G, Zhang Y, Li S, et al
    The Role of the Subthalamic Nucleus in Sequential Working Memory in De Novo Parkinson's Disease.
    Mov Disord. 2020 Oct 24. doi: 10.1002/mds.28344.
    PubMed     Abstract available


  714. VAN DER HEIDE A, Meinders MJ, Speckens AEM, Peerbolte TF, et al
    Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms.
    Mov Disord. 2020 Oct 23. doi: 10.1002/mds.28345.
    PubMed     Abstract available


  715. FU JF, Matarazzo M, McKenzie J, Neilson N, et al
    Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
    Mov Disord. 2020 Oct 22. doi: 10.1002/mds.28340.
    PubMed     Abstract available


  716. YIN W, Lof M, Pedersen NL, Sandin S, et al
    Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study.
    Mov Disord. 2020 Oct 20. doi: 10.1002/mds.28314.
    PubMed     Abstract available


  717. TAKEDA A, Takahashi R, Tsuboi Y, Nomoto M, et al
    Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients With Motor Fluctuations.
    Mov Disord. 2020 Oct 19. doi: 10.1002/mds.28322.
    PubMed     Abstract available


  718. LOWES H, Robertson F, Pyle A, Hussain R, et al
    The human coronavirus receptor ANPEP (CD13) is overexpressed in Parkinson's disease.
    Mov Disord. 2020 Oct 18. doi: 10.1002/mds.28354.
    PubMed    


  719. SCHLOSSMACHER MG, Graybiel AM
    Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28316.
    PubMed     Abstract available


  720. TAKAMIYA A, Seki M, Kudo S, Yoshizaki T, et al
    Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28335.
    PubMed     Abstract available


  721. MESTRE TA, Kessler D, Cote D, Liddy C, et al
    Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson's Disease.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28332.
    PubMed     Abstract available


  722. BELVISI D, Fabbrini A, De Bartolo MI, Costanzo M, et al
    The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes.
    Mov Disord. 2020 Oct 10. doi: 10.1002/mds.28321.
    PubMed     Abstract available


  723. DAHODWALA N, Li P, Jahnke J, Ladage VP, et al
    Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population.
    Mov Disord. 2020 Oct 8. doi: 10.1002/mds.28265.
    PubMed     Abstract available


  724. SANTIN MDN, Voulleminot P, Vrillon A, Hainque E, et al
    Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study.
    Mov Disord. 2020 Oct 6. doi: 10.1002/mds.28320.
    PubMed     Abstract available


  725. ISRAEL Z, Asch N
    Reversing a Model of Parkinson's Disease With In Situ Converted Nigral Neurons.
    Mov Disord. 2020 Oct 5. doi: 10.1002/mds.28306.
    PubMed    


  726. BONVEGNA S, Straccia G, Golfre Andreasi N, Elia AE, et al
    Parkinsonism and Nigrostriatal Damage Secondary to CSF1R-Related Primary Microgliopathy.
    Mov Disord. 2020 Oct 3. doi: 10.1002/mds.28290.
    PubMed    


  727. KANE PB, Benjamin DM, Barker RA, Lang AE, et al
    Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28319.
    PubMed     Abstract available


  728. TSUBOI T, Charbel M, Peterside DT, Rana M, et al
    Pallidal Connectivity Profiling of Stimulation-Induced Dyskinesia in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28324.
    PubMed     Abstract available


  729. IWAKI H, Blauwendraat C, Leonard HL, Makarious MB, et al
    Differences in the Presentation and Progression of Parkinson's Disease by Sex.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28312.
    PubMed     Abstract available


  730. MUFTI K, Rudakou U, Yu E, Krohn L, et al
    Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28318.
    PubMed     Abstract available


  731. ACHBANI A, Sine H, Naciri A, Baba MA, et al
    Reply to: "Can the 2019 Novel Coronavirus Cause Parkinson's Disease?"
    Mov Disord. 2020;35:1726.
    PubMed    


  732. HURWITZ B, Lees AJ, Walusinski O
    Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease.
    Mov Disord. 2020;35:1880-1881.
    PubMed    


  733. SULLIVAN R, Yau WY, Chelban V, Rossi S, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1890-1891.
    PubMed    


  734. DA SILVA SCHMITT G, Martinez ARM, da Graca FF, de Lima FD, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1889-1890.
    PubMed    


  735. AGUIRRE-PADILLA DH, Lozano AM, Fasano A
    Reply to: "Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?"
    Mov Disord. 2020;35:1883.
    PubMed    


  736. MONTGOMERY EB JR
    Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2020;35:1891.
    PubMed    


  737. CURY RG, Carra RB, Capato TTC, Teixeira MJ, et al
    Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?
    Mov Disord. 2020;35:1882-1883.
    PubMed    


  738. MONJE MHG, Martinez-Fernandez R
    Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Parkinsonism: Is There Evidence for Concern?
    Mov Disord. 2020;35:1725.
    PubMed    


  739. ALVES M, Caldeira D, Reimao S, Ferro JM, et al
    N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease.
    Mov Disord. 2020;35:1886-1887.
    PubMed    


  740. CHOE CU, Petersen E, Potter-Nerger M, Buhmann C, et al
    Reply to: "N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease".
    Mov Disord. 2020;35:1888.
    PubMed    


  741. LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
    Reply to: "Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease".
    Mov Disord. 2020;35:1882.
    PubMed    


  742. CROTTY GF, Lo RY, Schwarzschild MA
    If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?
    Mov Disord. 2020;35:1727-1730.
    PubMed    


    September 2020
  743. BLUMENREICH S, Jenkins BJ, Barav OB, Milenkovic I, et al
    The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28232.
    PubMed    


  744. RAJPUT AH, Kish SJ
    Professor Oleh Hornykiewicz, MD (1926-2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28317.
    PubMed    


  745. AL ALI J, Vaine CA, Shah S, Campion L, et al
    TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2020 Sep 25. doi: 10.1002/mds.28305.
    PubMed     Abstract available


  746. ZHANG X
    Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease".
    Mov Disord. 2020;35:1695.
    PubMed    


  747. LU C, Amundsen Huffmaster SL, Louie KH, Sovell-Brown K, et al
    Pallidal Oscillation Dynamics Following Cessation of Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2020;35:1697-1698.
    PubMed    


  748. SPEECKAERT MM, Speeckaert R, Delanghe JR
    Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1497.
    PubMed    


  749. CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
    Reply to: 'Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease"'.
    Mov Disord. 2020;35:1695-1697.
    PubMed    


  750. NEUMANN WJ, Feldmann L, Kuhn AA
    Reply to: Pallidal Low-Frequency Activity in Dystonia and Subthalamic Beta Activity in Parkinson's Disease.
    Mov Disord. 2020;35:1699.
    PubMed    


  751. CEREDA E, Fasano A, Pezzoli G
    Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1498.
    PubMed    


  752. WEIL RS
    Visual Dysfunction and Parkinson's Disease.
    Mov Disord. 2020;35:1499-1501.
    PubMed    


    August 2020
  753. MARKAKI I, Bergstrom S, Tsitsi P, Remnestal J, et al
    Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28192.
    PubMed     Abstract available


    July 2020
  754. LERCHE S, Wurster I, Roben B, Zimmermann M, et al
    CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Mov Disord. 2020;35:1138-1144.
    PubMed     Abstract available


    February 2020
  755. MAHATO AK, Kopra J, Renko JM, Visnapuu T, et al
    Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
    Mov Disord. 2020;35:245-255.
    PubMed     Abstract available


  756. RAPPEL P, Grosberg S, Arkadir D, Linetsky E, et al
    Theta-alpha oscillations characterize emotional subregion in the human ventral subthalamic nucleus.
    Mov Disord. 2020;35:337-343.
    PubMed     Abstract available


  757. MARTINEZ E, Pasquereau B, Saga Y, Metereau E, et al
    The anterior caudate nucleus supports impulsive choices triggered by pramipexole.
    Mov Disord. 2020;35:296-305.
    PubMed     Abstract available


  758. LEE JY, Ahn J, Oh S, Shin JY, et al
    Retina thickness as a marker of neurodegeneration in prodromal lewy body disease.
    Mov Disord. 2020;35:349-354.
    PubMed     Abstract available


    January 2020
  759. BELLOMO G, Paciotti S, Gatticchi L, Parnetti L, et al
    The vicious cycle between alpha-synuclein aggregation and autophagic-lysosomal dysfunction.
    Mov Disord. 2020;35:34-44.
    PubMed     Abstract available


  760. PYATIGORSKAYA N, Yahia-Cherif L, Gaurav R, Ewenczyk C, et al
    Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
    Mov Disord. 2020;35:161-170.
    PubMed     Abstract available


  761. COUGHLIN DG, Hurtig HI, Irwin DJ
    Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.
    Mov Disord. 2020;35:5-19.
    PubMed     Abstract available


  762. CHAUDHURI KR, Schrag A, Weintraub D, Rizos A, et al
    The movement disorder society nonmotor rating scale: Initial validation study.
    Mov Disord. 2020;35:116-133.
    PubMed     Abstract available


  763. RESPONDEK G, Grimm MJ, Piot I, Arzberger T, et al
    Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
    Mov Disord. 2020;35:171-176.
    PubMed     Abstract available


  764. ALCALAY RN, Hsieh F, Tengstrand E, Padmanabhan S, et al
    Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
    Mov Disord. 2020;35:134-141.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.